<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension - Rolim-de-Moura, CR - 2022 | Cochrane Library</title> <meta content="Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension - Rolim-de-Moura, CR - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003919.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension - Rolim-de-Moura, CR - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003919.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003919.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension" name="citation_title"/> <meta content="Christiane R Rolim-de-Moura" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="chrm@terra.com.br" name="citation_author_email"/> <meta content="Augusto Paranhos Jr" name="citation_author"/> <meta content="Escola Paulista de Medicina, Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Mohamed Loutfi" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="David Burton" name="citation_author"/> <meta content="Bradford Teaching Hospitals NHS Trust" name="citation_author_institution"/> <meta content="Richard Wormald" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="Jennifer R Evans" name="citation_author"/> <meta content="London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD003919.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/08/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003919.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003919.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003919.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Argon [therapeutic use]; *Glaucoma [surgery]; *Glaucoma, Open-Angle [drug therapy, surgery]; *Ocular Hypertension [etiology, surgery]; *Optic Nerve Diseases [etiology, surgery]; *Trabeculectomy [adverse effects, methods]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003919.pub3&amp;doi=10.1002/14651858.CD003919.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="f00EizoA";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003919\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003919\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ko","ms","id","fa","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003919.pub3",title:"Laser trabeculoplasty for open\\u2010angle glaucoma and ocular hypertension",firstPublishedDate:"Aug 9, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003919.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003919.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003919.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003919.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003919.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003919.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003919.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003919.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003919.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003919.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3883 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003919.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-sec-0114"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/appendices#CD003919-sec-0119"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/supinfo/CD003919StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/supinfo/CD003919StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information#CD003919-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Christiane R Rolim-de-Moura</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information#CD003919-cr-0005">Augusto Paranhos Jr</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information#CD003919-cr-0006">Mohamed Loutfi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information#CD003919-cr-0007">David Burton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information#CD003919-cr-0008">Richard Wormald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information#CD003919-cr-0009">Jennifer R Evans</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information/en#CD003919-sec-0137">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 August 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003919.pub3">https://doi.org/10.1002/14651858.CD003919.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003919-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003919-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003919-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003919-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003919-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003919-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003919-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003919-abs-0001" lang="en"> <section id="CD003919-sec-0001"> <h3 class="title" id="CD003919-sec-0001">Background</h3> <p>Open‐angle glaucoma (OAG) is an important cause of blindness worldwide. Laser trabeculoplasty, a treatment modality, still does not have a clear position in the treatment sequence. </p> </section> <section id="CD003919-sec-0002"> <h3 class="title" id="CD003919-sec-0002">Objectives</h3> <p>To assess the effects of laser trabeculoplasty for treating OAG and ocular hypertension (OHT) when compared to medication, glaucoma surgery or no intervention. We also wished to compare the effectiveness of different laser trabeculoplasty technologies for treating OAG and OHT. </p> </section> <section id="CD003919-sec-0003"> <h3 class="title" id="CD003919-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2021, Issue 10); Ovid MEDLINE; Ovid Embase; the ISRCTN registry; LILACS, ClinicalTrials.gov and the WHO ICTRP. The date of the search was 28 October 2021. We also contacted researchers in the field. </p> </section> <section id="CD003919-sec-0004"> <h3 class="title" id="CD003919-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing laser trabeculoplasty with no intervention, with medical treatment, or with surgery in people with OAG or OHT. We also included trials comparing different types of laser trabeculoplasty technologies. </p> </section> <section id="CD003919-sec-0005"> <h3 class="title" id="CD003919-sec-0005">Data collection and analysis</h3> <p>We used standard methods expected by Cochrane. Two authors screened search results and extracted data independently. We considered the following outcomes at 24 months: failure to control intraocular pressure (IOP), failure to stabilise visual field progression, failure to stabilise optic neuropathy progression, adverse effects, quality of life, and costs. We graded the 'certainty' of the evidence using GRADE. </p> </section> <section id="CD003919-sec-0006"> <h3 class="title" id="CD003919-sec-0006">Main results</h3> <p>We included 40 studies (5613 eyes of 4028 people) in this review. The majority of the studies were conducted in Europe and in the USA. Most of the studies were at risk of performance and/or detection bias as they were unmasked. None of the studies were judged as having low risk of bias for all domains. We did not identify any studies of laser trabeculoplasty alone versus no intervention. </p> <p><i>Laser trabeculoplasty versus medication</i> </p> <p>Fourteen studies compared laser trabeculoplasty with medication in either people with primary OAG (7 studies) or primary or secondary OAG (7 studies); five of the 14 studies also included participants with OHT. Six studies used argon laser trabeculoplasty and eight studies used selective laser trabeculoplasty. There was considerable clinical and methodological diversity in these studies leading to statistical heterogeneity in results for the primary outcome "failure to control IOP" at 24 months.  Risk ratios (RRs) ranged from 0.43 in favour of laser trabeculoplasty to 1.87 in favour of medication (5 studies, I<sup>2</sup> = 89%). Studies of argon laser compared with medication were more likely to show a beneficial effect compared with studies of selective laser (test for interaction P = 0.0001) but the argon laser studies were older and the medication comparator group in those studies may have been less effective. We considered this to be low‐certainty evidence because the trials were at risk of bias (they were not masked) and there was unexplained heterogeneity. There was evidence from two studies (624 eyes) that argon laser treatment was associated with less failure to stabilise visual field progression compared with medication (7% versus 11%, RR 0.70, 95% CI 0.42 to 1.16) at 24 months and one further large recent study of selective laser also reported a reduced risk of failure at 48 months (17% versus 26%) RR 0.65, 95% CI 0.52 to 0.81, 1178 eyes). We judged this outcome as moderate‐certainty evidence, downgrading for risk of bias. There was only very low‐certainty evidence on optic neuropathy progression. Adverse effects were more commonly seen in the laser trabeculoplasty group including peripheral anterior synechiae (PAS) associated with argon laser (32% versus 26%, RR 11.74, 95% CI 5.94 to 23.22; 624 eyes; 2 RCTs; low‐certainty evidence); 5% of participants treated with laser in three studies of selective laser group had early IOP spikes (moderate‐certainty evidence). One UK‐based study provided moderate‐certainty evidence that laser trabeculoplasty was more cost‐effective.  </p> <p><i>Laser trabeculoplasty versus trabeculectomy</i> </p> <p>Three studies compared laser trabeculoplasty with trabeculectomy. All three studies enrolled participants with OAG (primary or secondary) and used argon laser. People receiving laser trabeculoplasty may have a higher risk of uncontrolled IOP at 24 months compared with people receiving trabeculectomy (16% versus 8%, RR 2.12, 95% CI 1.44 to 3.11; 901 eyes; 2 RCTs). We judged this to be low‐certainty evidence because of risk of bias (trials were not masked) and there was inconsistency between the two trials (I<sup>2</sup> = 68%). There was limited evidence on visual field progression suggesting a higher risk of failure with laser trabeculoplasty. There was no information on optic neuropathy progression, quality of life or costs. PAS formation and IOP spikes were not reported but in one study trabeculectomy was associated with an increased risk of cataract (RR 1.78, 95% CI 1.46 to 2.16) (very low‐certainty evidence). </p> </section> <section id="CD003919-sec-0007"> <h3 class="title" id="CD003919-sec-0007">Authors' conclusions</h3> <p>Laser trabeculoplasty may work better than topical medication in slowing down the progression of open‐angle glaucoma (rate of visual field loss) and may be similar to modern eye drops in controlling eye pressure at a lower cost. It is not associated with serious unwanted effects, particularly for the newer types of trabeculoplasty, such as selective laser trabeculoplasty.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003919-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003919-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003919-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003919-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003919-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003919-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD003919-abs-0015">Magyar</a> </li> <li class="section-language"> <a class="" href="full/id#CD003919-abs-0010">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003919-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003919-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003919-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003919-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003919-abs-0002" lang="en"> <h3>Laser trabeculoplasty for open‐angle glaucoma</h3> <p><b>Key messages</b> </p> <p>•   Laser trabeculoplasty may work better than topical medication (eye drops) in slowing down the progression of open‐angle glaucoma (rate of visual field loss i.e. vision loss at the edges of vision) and may be similar to modern eye drops in controlling eye pressure at a lower cost. It is not associated with any serious unwanted effects, particularly for the newer types of trabeculoplasty, such as selective laser trabeculoplasty.   </p> <p>•   Laser trabeculoplasty appears to work less well than trabeculectomy (surgery for glaucoma).  </p> <p><b>What is open‐angle glaucoma? </b> </p> <p>Glaucoma is an eye disease where the nerve that connects the eye to the brain (optic nerve) is damaged. Usually, this happens because the pressure inside the eye (intraocular pressure) is too high, probably because the drainage channels in the eye have become blocked.  </p> <p><b>How is open‐angle glaucoma treated? </b> </p> <p>The aim of treatment for glaucoma is to reduce the pressure in the eye to protect the optic nerve from more damage. Reducing the pressure in the eye can be done by eye drops, laser treatment, or surgery. Laser trabeculoplasty involves opening up the blocked drainage channels in the eye. </p> <p><b>What did we want to find out?</b> </p> <p>The aim of this Cochrane Review is to find out how well laser trabeculoplasty works as a treatment for open‐angle glaucoma.  </p> <p><b>What did we do?</b> </p> <p>This review compared laser treatment (laser trabeculoplasty) with topical medication (eye drops) and surgery (trabeculectomy). Cochrane researchers collected and analysed all relevant studies to answer this question.  </p> <p><b>What did we find? </b><br/>Cochrane researchers found 40 studies. These studies were mainly from Europe and the USA. </p> <p>The results were as follows:</p> <p>•   Different studies found different effects on eye pressure when comparing laser trabeculoplasty with eye drops. Older studies were more likely to show a benefit of laser trabeculoplasty which may be because the eye drops in these older studies did not work as well as modern eye drops (low‐certainty evidence). Three studies showed a benefit of trabeculoplasty over eye drops for avoiding visual field progression at 24 months (argon) and 48 months (selective) (moderate‐certainty evidence, downgraded for risk bias). </p> <p>•   Harmful effects were more common in the laser trabeculoplasty group and included more cases where the iris was stuck to the edge of the drainage mechanism inside the eye (peripheral anterior synaechiae) but this was seen only with older types of laser (argon) trabeculoplasty (low‐certainty evidence). </p> <p>•   People receiving laser trabeculoplasty may be more likely to have pressure in the eye that is too high compared with people who had surgery (trabeculectomy) (low‐certainty evidence). </p> <p>•   Surgery (trabeculectomy) may increase the risk of cataract compared with laser (very low‐certainty evidence). </p> <p>•   A number of studies compared different types of laser (argon, selective, diode, excimer, pattern scanning, titanium‐sapphire, and micropulse) but with inconclusive results. </p> <p><b>What are the limitations of the evidence? </b> </p> <p>Some of the studies were not masked and were not large enough to provide a reliable answer to the question. There have been changes over time in both laser and eye drops which meant that, for some outcomes, there were different effects in different studies.  </p> <p><b>How up‐to‐date is this evidence?</b><br/>Cochrane Review authors searched for studies that had been published up to 28 October 2021. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003919-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003919-sec-0114"></div> <h3 class="title" id="CD003919-sec-0115">Implications for practice</h3> <section id="CD003919-sec-0115"> <p>Currently, moderate‐certainty evidence is available to guide clinical decision‐making in the use of laser trabeculoplasty. It may provide some advantages in control over topical medication, especially at 24 months of follow‐up without serious adverse effects. It probably reduces the risk of visual field progression when treatment is done with selective laser trabeculoplasty in naive primary open‐angle glaucoma and ocular hypertension patients. In a specific health system, laser trabeculoplasty was more cost‐effective as initial treatment than medication. </p> <p>However, it appears to work less well than trabeculectomy.</p> <p>Diode laser and selective trabeculoplasty had similar side effects when compared to ALT. Micropulse laser trabeculoplasty and pattern scanning laser trabeculoplasty had similar effects when compared to SLT and different protocols of laser trabeculoplasty have similar risks of uncontrolled IOP, but higher power levels such as 800 mW in conventional ALT seemed to increase the risk of PAS formation in ALT. </p> <p>The findings suggest that laser trabeculoplasty might be a useful initial treatment in people with early glaucoma when the availability of medicines or their cost or both might reduce the likelihood of compliance in the real world. This might be of particular relevance in lower‐income countries but the concern will remain about the duration of effect and there may be issues regarding the maintenance of equipment.  </p> <p>There is no doubt that laser trabeculoplasty can have an effect on IOP control. A treatment delivered at a single sitting that is not invasive and has minimal side effects and is relatively cheap is probably worth looking at again very closely. </p> </section> <h3 class="title" id="CD003919-sec-0116">Implications for research</h3> <section id="CD003919-sec-0116"> <p>Further RCTs are necessary for different populations, particularly in lower‐income settings. Laser trabeculoplasty should be compared to medication and trabeculectomy, to determine if there is actually a difference in response to laser in different contexts and stages of the disease.    </p> <p>Much can be done to improve the quality of RCTs addressing this important question. Trialists have assumed that masking of participants is not possible but, since such a large placebo effect was demonstrated in the European Glaucoma Prevention Study, it has become all the more important to provide single‐ if not double‐masking. Double‐masking might be achievable with the use of a specially devised pair of gonioscopy lenses, one of which absorbs laser energy. In such a circumstance, a standard laser power would have to be used and some degree of unmasking may occur if the operator notes blanching of trabecular pigment or bubbling but this is still probably better than no masking. In any event, masking of intervention status by those determining outcome should always be employed. </p> <p>The other vitally important question is whether we can gain a better understanding of the determinants of responsiveness to laser trabeculoplasty; who responds and who does not and why? Related to this is discovering what determines the duration of effect and whether there is any way this can be predicted. </p> <p>And, finally, the choice of studying relevant outcomes, such as quality of life, visual field decay and cost‐effectiveness should be the goal of further RCTs. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003919-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003919-sec-0008"></div> <div class="table" id="CD003919-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Laser trabeculoplasty versus medication</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Laser trabeculoplasty versus medication</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with open‐angle glaucoma<br/><b>Setting:</b> eye hospital<br/><b>Intervention:</b> laser trabeculoplasty<br/><b>Comparison:</b> medication </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of eyes (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with medication</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with laser trabeculoplasty</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to control IOP</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Considerable clinical and methodological diversity leading to statistical heterogeneity (I<sup>2</sup> = 89%). Risk ratios ranged from 0.43 in favour of laser trabeculoplasty to 1.87 in favour of medication. Studies of argon laser compared with medication were more likely to show a beneficial effect compared with studies of selective laser (test for interaction P = 0.0001) but the argon laser studies were older and the medication comparator group in those studies may have been less effective. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to stabilise visual field progression</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/>(44 to 122) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/>(0.42 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both studies of argon laser. </p> <p>One further study found RR 0.65 (0.52 to 0.81) in favour of selective laser at 48 months.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to stabilise optic neuropathy progression</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/>(44 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73 (0.44 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1,2,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both studies of argon laser. One further study found RR of 0.68 (0.11 to 4.08) in favour of selective laser at 36 months ( 5 events only).  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measures</p> <p>follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One study reported little difference in scores on 12 domains of the GOAT (Glaucoma Outcomes Assessment Tool) at 24 months with the exception of 'social well‐being' whereby participants treated with selective laser reported a greater improvement (MD 0.28, 95% CI  0.03 to 0.53) but it was unclear if this difference was important to patients.  </p> <p>One study reported quality of life as measured using EuroQol EQ‐5D 5 Levels was similar comparing selective laser and medication groups at 36 months (MD 0.01, 95% CI –0.01 to 0.03; P = 0·23).  </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>819 people (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects:<br/>PAS formation </p> <p>follow‐up: any time point</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1000<br/>(149 to 580) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 11.74<br/>(5.94 to 23.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both these studies were argon laser. No PAS events observed in three studies of selective laser. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects: IOP spikes</p> <p>follow‐up: any time point</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>21/429 (5%) of participants in the laser group had early IOP spikes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>429</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All three studies were selective laser.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Costs</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One UK‐based study considered ophthalmology costs and used a willingness‐to‐pay cut‐point of  £20,000 per quality‐adjusted life‐year gained. There was a strong probability (97%) that selective laser (as first‐line treatment) was more cost‐effective than topical medication (as first‐line treatment).  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1235 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is the median risk across the included studies.<br/><b>CI:</b> Confidence interval;<b>IOP:</b> intraocular pressure; <b>PAS</b> : peripheral anterior synechiae; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different </p> <p><b>Low‐certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different </p> <p><b>Very low‐certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): the trials were not masked. </p> <p><sup>2</sup>Downgraded for inconsistency (‐1): unexplained heterogeneity with study results ranging from 0.43 to 1.87 (for outcome, failure to control IOP) and between 0.5 and 1.0 (for outcome, failure to stablise optic neuropathy progression).  </p> <p><sup>3</sup>We did not downgrade for imprecision because an additional study at 48 months found a statistically significant effect of a similar order of magnitude. </p> <p><sup>4</sup>Downgraded for inconsistency (‐1): PAS events only seen in studies of argon laser </p> <p><sup>5</sup>Downgraded for imprecision (‐1): confidence intervals included risk ratios compatible with benefit or harm.  </p> <p><sup>6</sup>Downgraded for indirectness (‐1): results may not generalise globally.  </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003919-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Laser trabeculoplasty versus trabeculectomy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Laser trabeculoplasty versus trabeculectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with open‐angle glaucoma<br/><b>Setting:</b> eye hospital<br/><b>Intervention:</b> laser trabeculoplasty<br/><b>Comparison:</b> trabeculectomy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of eyes (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with trabeculectomy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with laser trabeculoplasty</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to control IOP</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1000<br/>(115 to 249) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.12</p> <p>(1.44 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>901<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1,2</sup><br/>LOW </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> = 68% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to stabilise visual field progression</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Limited data from follow‐up in one study suggested evidence of greater deterioration in the (argon) laser group compared with trabeculectomy at 5 years follow‐up.  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1,3</sup><br/>LOW </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to stabilise optic neuropathy progression</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects<br/>PAS formation </p> <p>follow‐up: any time point</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="2" valign="top"> <p>PAS formation and IOP spikes not reported, but in one study trabeculectomy was associated with an increased risk of cataract (RR 1.78, 95% CI 1.46 to 2.16). </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>789 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1,4</sup> </p> <p>VERY LOW<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects: IOP spikes</p> <p>follow‐up: any time point </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is the median risk across the included studies. </p> <p>** No events were observed with medication. We have assumed a low risk for illustrative purposes.<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b><br/>  </p> <p><b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different </p> <p><b>Low‐certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different </p> <p><b>Very low‐certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): none of the studies were masked and one study was at high risk of attrition bias. </p> <p><sup>2</sup>Downgraded for inconsistency (‐1): I<sup>2</sup> = 68% </p> <p><sup>3</sup>Downgraded for imprecision (‐1): wide confidence intervention crossed the line of no effect. </p> <p><sup>4</sup>Downgraded for imprecision (‐2): sparse data.  </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003919-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003919-sec-0009"></div> <section id="CD003919-sec-0010"> <h3 class="title" id="CD003919-sec-0010">Description of the condition</h3> <p>Projections estimate that the number of people with glaucoma worldwide (aged 40 to 80 years old) will increase from 64.3 million in 2013 to 111.8 million in 2040 and 11.1 million will become blind because of glaucoma. Prevalence of glaucoma in Europe and North America is estimated at 2.93% and 3.55% respectively (<a href="./references#CD003919-bbs2-0134" title="ThamYC , LiX , WongTY , QuigleyHA , AungT , ChengCY . Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology2014;121(11):2081-90.">Tham 2014</a>). Several studies suggest that people of African origin have three times higher rates of primary open‐angle glaucoma (POAG) compared with people of European or Asian origin. </p> <p>Glaucoma is described as a group of disorders with a common denominator; a characteristic optic neuropathy. Various risk factors are associated with glaucoma but increased intraocular pressure (IOP) is consistently one of the most important (<a href="./references#CD003919-bbs2-0132" title="AllinghamRR , DamjiKF , FreedmanS , MoroiSE , ShafranovG , ShieldsMB . Shields' Textbook of Glaucoma. 5th edition. Philadelphia: Lippinicott Williams &amp; Wilkins, 2005.">Shields 2005</a>). Primary open‐angle glaucoma has these characteristics, but also an open, normal‐appearing anterior chamber angle with no ocular or systemic abnormality that might account for the elevated IOP, that is consistently above 21 mmHg, at least in one eye (<a href="./references#CD003919-bbs2-0132" title="AllinghamRR , DamjiKF , FreedmanS , MoroiSE , ShafranovG , ShieldsMB . Shields' Textbook of Glaucoma. 5th edition. Philadelphia: Lippinicott Williams &amp; Wilkins, 2005.">Shields 2005</a>). Normal tension glaucoma has similar characteristics but IOP is not the most influential causative factor (<a href="./references#CD003919-bbs2-0132" title="AllinghamRR , DamjiKF , FreedmanS , MoroiSE , ShafranovG , ShieldsMB . Shields' Textbook of Glaucoma. 5th edition. Philadelphia: Lippinicott Williams &amp; Wilkins, 2005.">Shields 2005</a>). However, it is now widely accepted that dichotomising the disease into normal tension and POAG around an IOP of 21 mmHg or any other statistically derived figure is arbitrary and that there is a continuity or gradation of risk with increasing IOP which reflects the extent to which the disease is determined by elevated pressure. At lower levels of IOP, other mechanisms are believed to influence progression of the disease. Ocular hypertension (OH) is a condition in which eyes with normal angles, have IOP above 21 mmHg, but no detected lesion in optic nerve or visual field. The risk of conversion to POAG is already well established in the literature in some of these cases and IOP reduction is the only treatment known to avoid the progression in high‐risk cases (<a href="./references#CD003919-bbs2-0123" title="KassMA , HeuerDK , HigginbothamEJ , JohnsonCA , KeltnerJL , MillerJP , et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology2002;120(6):701-13.">Kass 2002</a>). </p> <p>Glaucoma secondary to pigment dispersion syndrome (pigmentary glaucoma) is a form of glaucoma where, although the anterior chamber angle is open, there is an unusually heavy dispersion of pigment, which may be significantly involved in the pathogenesis of elevated IOP. Pseudoexfoliation glaucoma or capsular glaucoma is another form of glaucoma with an open anterior chamber angle, but it is associated with a deposition of a proteinaceous material in the anterior segment of the eye. All these four entities are included in a group called open‐angle glaucoma (OAG). Glaucomatous neuropathy leads to visual field loss, initially in an arcuate or paracentral pattern extending to the periphery and ultimately to loss of central vision. </p> </section> <section id="CD003919-sec-0011"> <h3 class="title" id="CD003919-sec-0011">Description of the intervention</h3> <p>Reduction of IOP is still the goal of OAG treatment and it has been shown in a couple of systematic reviews to be important in preventing visual field deterioration (<a href="./references#CD003919-bbs2-0127" title="MaierPC , FunkJ , SchwarzerG , AntesG , Fal k-YtterYT . Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ2005;331(7509):134-9.">Maier 2005</a>; <a href="./references#CD003919-bbs2-0136" title="VassC , HirnC , SychaT , FindlO , BauerP , SchmettererL . Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD003167. [DOI: 10.1002/14651858.CD003167.pub2]">Vass 2007</a>). Medical therapy is usually the first‐line therapy and there are currently many combinations of hypotensive topical medicines that can lead to a satisfactory IOP reduction (<a href="./references#CD003919-bbs2-0126" title="LiT , LindsleyK , RouseB , HongH , ShiQ , FriedmanDS , et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology2016;123(1):129-40.">Li 2016</a>; <a href="./references#CD003919-bbs2-0130" title="RealiniT , FechtnerRD . 56,000 ways to treat glaucoma. Ophthalmology2002;109(11):1955-6.">Realini 2002</a>). Surgical approaches are usually reserved for cases in which good IOP control is not achieved with medication (<a href="./references#CD003919-bbs2-0132" title="AllinghamRR , DamjiKF , FreedmanS , MoroiSE , ShafranovG , ShieldsMB . Shields' Textbook of Glaucoma. 5th edition. Philadelphia: Lippinicott Williams &amp; Wilkins, 2005.">Shields 2005</a>) because of the risks of surgical complications. Laser trabeculoplasty is a non‐invasive technique that has been employed as first‐line or adjunctive therapy, or in order to avoid or delay surgical procedures. </p> <p>Treating the trabecular meshwork with laser in human eyes was first described by <a href="./references#CD003919-bbs2-0124" title="KrasnovMM . Laseropuncture of anterior chamber angle in glaucoma. American Journal of Ophthalmology1973;75(4):674-8.">Krasnov 1973</a>. He believed the ruby laser caused a 'puncture' of the meshwork and thus an improvement in aqueous filtration. Later, <a href="./references#CD003919-bbs2-0138" title="WorthenDM , WickhamMG . Argon laser trabeculotomy. Transactions of the American Academy of Ophthalmology1974;78:371-5.">Worthen 1974</a> described a series of uncontrolled OAG patients treated with argon laser, calling the procedure a laser trabeculotomy. <a href="./references#CD003919-bbs2-0137" title="WiseJB , WitterSL . Argon laser therapy for open-angle glaucoma. A pilot study. Archives of Ophthalmology1979;97(2):319-22.">Wise 1979</a> followed a series of 56 cases submitted to trabecular argon laser treatment for 18 months and considered this to be an effective alternative to filtration surgery. With a longer follow‐up, <a href="./references#CD003919-bbs2-0131" title="SchwartzAL , LoveDC , SchwartzMA . Long-term follow-up of argon laser trabeculoplasty for uncontrolled open-angle glaucoma. Archives of Ophthalmology1985;103(10):1482-4.">Schwartz 1985</a> observed a decreasing success rate over time and poorer IOP control in black people. Some authors observed an improvement in visual fields, most likely related to laser trabeculoplasty‐induced IOP reduction (<a href="./references#CD003919-bbs2-0135" title="TraversoCE , SpaethGL , StaritaRJ , FellmanRL , GreenidgeKC , PoryzeesE . Factors affecting the results of argon laser trabeculoplasty in open-angle glaucoma. Ophthalmic Surgery1986;17(9):554-9.">Traverso 1986</a>), but this finding was not reproduced in other studies (<a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>). Peripheral anterior synechiae (PAS) and IOP spikes were frequently described complications of argon laser trabeculoplasty (ALT) (<a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>). </p> <p>In 1995, Latina and Park were the first to conduct selective laser treatment of pigment‐containing trabecular meshwork tissue. They demonstrated that by using a Q‐switched frequency‐doubled 532‐nm Nd:YAG laser for a short duration (3ns) and power range of 0.2 to 2 mJ, they could selectively target the pigment‐containing trabecular meshwork with minimal thermal diffusion to non‐pigmented cells, potentially a major safety advantage compared to argon laser. This technique was subsequently named selective laser trabeculoplasty (SLT); many studies have assessed its safety and efficacy. In a randomised clinical trial, a success rate of over 70% was demonstrated in people who received SLT up to 30 months following treatment (<a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>). A new modality of ALT has been developed recently, using low radiance, to reduce IOP and minimise trabecular tissue damage. It is called Micropulse laser trabeculoplasty (<a href="./references#CD003919-bbs2-0051" title="Detry-MorelM , MuschartF , PourjavanS . Micropulse diode laser (810 nm) versus argon laser trabeculoplasty in the treatment of open-angle glaucoma: comparative short-term safety and efficacy profile. Bulletin de la Societe Belge d'Ophtalmologie2008;308:21-8. ">Detry‐Morel 2008</a>). </p> </section> <section id="CD003919-sec-0012"> <h3 class="title" id="CD003919-sec-0012">How the intervention might work</h3> <p>During the development of the technology, authors proposed laser trabeculoplasty for managing OAG as an effective alternative to filtration surgery, but currently laser trabeculoplasty is being considered as a first‐line alternative to medical treatment and could delay the need for medical or surgical intervention (<a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>; <a href="./references#CD003919-bbs2-0128" title="McIlraithI , StrasfeldM , ColevG , HutnikCM . Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. Journal of Glaucoma2006;15(2):124-30.">McIlraith 2006</a>; <a href="./references#CD003919-bbs2-0129" title="MelamedS , Ben SimonGJ , Levkovitch-VerbinH . Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study. Archives of Ophthalmology2003;121(17):957-60.">Melamed 2003</a>; <a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>) for IOP reduction. The exact mechanism of action of ALT/SLT is still speculative but it is not due to perforation of the meshwork. One theory is that it causes circumferential contraction of the meshwork, thereby opening spaces between the meshwork beams. For SLT, there is thought to be a rejuvenative stimulus to the meshwork endothelium. </p> </section> <section id="CD003919-sec-0013"> <h3 class="title" id="CD003919-sec-0013">Why it is important to do this review</h3> <p>Although studies suggest a positive effect of laser trabeculoplasty for controlling IOP in OAG and OH, there is no consensus on the role of laser trabeculoplasty in the treatment pathway for these diseases and its use varies widely in practice in different parts of the world. This reflects underlying uncertainty of its effectiveness and, hence, there is a need for a systematic review of all the best evidence of the effectiveness of this intervention. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003919-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003919-sec-0014"></div> <p>To assess the effects of laser trabeculoplasty for treating OAG and OH when compared to medication, glaucoma surgery or no intervention. We also wished to compare the effectiveness of different laser trabeculoplasty technologies for treating OAG and OH.  </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003919-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003919-sec-0015"></div> <section id="CD003919-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003919-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) only. We included both parallel‐group designs, whereby people were randomly allocated to treatment, and within‐person studies i.e. 'split‐body' designs where eyes were randomly allocated to treatment.  </p> </section> <section id="CD003919-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants in the trials were people with any diagnosis of OAG (this included primary, secondary pigment dispersion, corticosteroid‐induced glaucoma and exfoliation or pseudoexfoliation syndromes) and OH. Gender, age and nationality were not used as exclusion criteria. We excluded studies where people were previously treated with laser.  </p> </section> <section id="CD003919-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials where any laser trabeculoplasty technique was compared with one or more of the following: </p> <p> <ul id="CD003919-list-0001"> <li> <p>no intervention (untreated control groups);</p> </li> <li> <p>medical ocular hypotensive therapy;</p> </li> <li> <p>laser trabeculoplasty combined with medical ocular hypotensive therapy;</p> </li> <li> <p>glaucoma drainage surgery;</p> </li> <li> <p>alternative laser trabeculoplasty techniques.</p> </li> </ul> </p> <p>We included studies where laser trabeculoplasty was combined with medication where this was compared with medication alone, but we excluded studies where laser trabeculoplasty was combined with medication and compared to no treatment. </p> </section> <section id="CD003919-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We considered the following outcomes measure. Reporting of these outcome measures was not a criterion for inclusion however we excluded studies where it was clear that none of these outcomes were measured  .  </p> <section id="CD003919-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003919-list-0002"> <li> <p>failure to control IOP (as defined by study investigators);</p> </li> <li> <p>failure to stabilise visual field progression (as defined by study investigators);</p> </li> <li> <p>failure to stabilise optic neuropathy progression (as defined by study investigators).</p> </li> </ul> </p> </section> <section id="CD003919-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003919-list-0003"> <li> <p>quality of life measures as available in the trial reports;</p> </li> <li> <p>economic data as available in the trial reports.</p> </li> </ul> </p> <p>A minimum six months follow‐up was required; trials with less than six months of follow‐up were excluded. </p> <p>We also collected outcomes at 12 and 24 months, when possible.</p> <section id="CD003919-sec-0023"> <h6 class="title">Adverse effects</h6> <p>Adverse effects (severe, minor) including: IOP spikes; uveitis; cyclitis; hyphema; PAS formation; corneal oedema; persistent IOP elevation; loss of vision (central island); bronchospasm; corneal endothelial cell loss </p> </section> </section> </section> </section> <section id="CD003919-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003919-sec-0025"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the following electronic databases for RCTs and controlled clinical trials. There were no language or publication year restrictions. The date of the search was 28 October 2021. </p> <p> <ul id="CD003919-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 10) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched 28 October 2021 (<a href="./appendices#CD003919-sec-0120">Appendix 1</a>). </p> </li> <li> <p>MEDLINE Ovid (1946 to 28 October 2021) (<a href="./appendices#CD003919-sec-0121">Appendix 2</a>). </p> </li> <li> <p>Embase Ovid (1980 to 28 October 2021) (<a href="./appendices#CD003919-sec-0122">Appendix 3</a>). </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information Database (1982 to 28 October 2021). (<a href="./appendices#CD003919-sec-0123">Appendix 4</a>). </p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>; searched 28 October 2021) (<a href="./appendices#CD003919-sec-0124">Appendix 5</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 28 October 2021) (<a href="./appendices#CD003919-sec-0125">Appendix 6</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; searched 28 October 2021) (<a href="./appendices#CD003919-sec-0126">Appendix 7</a>). </p> </li> </ul> </p> </section> <section id="CD003919-sec-0026"> <h4 class="title">Searching other resources</h4> <p>The authors of the included studies and experts in the field were contacted to find out if they knew of any published or unpublished RCTs of laser trabeculoplasty for OAG which had not been identified. We used the Science Citation Index to search for reports that cited the studies included in this review. We also searched the reference lists of included study reports to check for details of further relevant trials. </p> </section> </section> <section id="CD003919-sec-0027"> <h3 class="title" id="CD003919-sec-0027">Data collection and analysis</h3> <section id="CD003919-sec-0028"> <h4 class="title">Selection of studies</h4> <p>Two authors working independently (AP/CRM, DB/ML or CRM/JE), screened the abstracts of all publications that were found by the searches. Full‐text reports of all potentially relevant studies were obtained and were assessed against the inclusion criteria. Disagreements were discussed and final decisions were adopted after discussion, including a third author as necessary (RW). For the current update, results of searches were entered into internet‐based review management software (<a href="./references#CD003919-bbs2-0118" title="Covidence. Melbourne, Australia: Veritas Health Innovation, (accessed 10 January 2022). Available at covidence.org.">Covidence</a>).  </p> <p>Excluded studies were documented in the <a href="./references#CD003919-sec-0144" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD003919-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>In the first version of the review, two authors extracted data independently (CRM, AP); in the current update, two authors (DB/ML or CRM/JE) also extracted data independently. We discussed any disagreements and the decisions were documented. Where necessary, the authors of the studies were contacted to help resolve the issue. </p> <p>Where means or standard deviations were not available, we tried to calculate these values based on extracting data from graphics. </p> </section> <section id="CD003919-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (AP/CRM, CRM/JE) independently assessed risk of bias in the included studies using Cochrane's tool for assessing risk of bias, disagreements were discussed, and conciliation was achieved.  </p> <p>We graded risk of bias as: low risk of bias, high risk of bias or unclear using the criteria as listed in <a href="./appendices#CD003919-sec-0127">Appendix 8</a>. Attempts to contact the authors of the trials which were graded as unclear were made for further information. </p> </section> <section id="CD003919-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>Dichotomous outcomes were analysed by calculating the risk ratio for each trial with 95% confidence intervals. </p> <p>Continuous outcomes were analysed according to the difference in mean treatment effects (mean difference) with 95% confidence intervals. </p> </section> <section id="CD003919-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>There were three types of studies included in this review with different implications for unit of analysis:   </p> <p> <ol id="CD003919-list-0005"> <li> <p>Parallel‐group studies: in these studies, people were randomly allocated to intervention or comparator and one eye selected as the 'study eye'. In this case, there was no unit of analysis issue as the unit of analysis was the same as the unit of randomisation. We documented how the selection of the study eye was done.   </p> </li> <li> <p>Clustered studies: in these studies, people were randomly allocated to intervention or comparator and results for both eyes were reported. This means that the data can be considered to be 'clustered' and ideally effect estimates and 95% confidence intervals should be adjusted for the extra variation introduced by the cluster design.    </p> </li> <li> <p>Within‐person studies: in these studies, eyes were randomly allocated to intervention or comparator with a paired or  'split‐body' design; one eye receiving the intervention and the other eye receiving the comparator. Ideally, any analysis of these data should report a paired analysis. </p> </li> </ol> </p> <p>For the designs with a potential unit of analysis issue (2 and 3), we checked whether a correct analysis was reported taking into account the unit of analysis issue specific to that study design. If a correct analysis was reported, we used these correct estimates and variance, entering the effect estimate and adjusted standard error using the generic inverse variance approach in Revman. If a correct analysis was not reported, we used the data on eyes as reported.  </p> <p>For analyses that contributed to the summary of findings tables (<a href="./full#CD003919-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD003919-tbl-0002">summary of findings Table 2</a>), we performed a sensitivity analysis to check how robust the findings were under reasonable assumptions of within‐person correlation and following methods outlined in chapter 23 of the Cochrane Handbook (<a href="./references#CD003919-bbs2-0122" title="HigginsJPT ,  Eldridge S, LiT . Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020), Cochrane 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). These methods were:  </p> <p> <ul id="CD003919-list-0006"> <li> <p>For clustered data, we multiplied the standard error of the effect estimate for the study (if clustering had been ignored) by the square root of the design effect. We calculated the design effect using the formula 1 ‐ (M ‐ 1) * ICC where M = average cluster size and ICC is the intra‐cluster correlation coefficient. We assumed an ICC of 0.05. </p> </li> <li> <p>For within‐person studies not reporting a correct analysis, we used the Becker‐Balagtas method for dichotomous outcomes (<a href="./references#CD003919-bbs2-0133" title="StedmanMR , CurtinF , ElbourneDR , KesselheimAS , BrookhartMA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2011;40(6):1732-4.">Stedman 2011</a>).  </p> </li> </ul> </p> </section> <section id="CD003919-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>We used data as reported by included studies, which was largely complete case analysis. </p> </section> <section id="CD003919-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological diversity by careful perusal of the study reports and statistical heterogeneity in the results of the trials by inspection of graphical presentations and by performing a Chi<sup>2</sup> test and an I<sup>2</sup> test. Following the guidance in the Cochrane Handbook, we considered an I<sup>2</sup> value of 50% or greater to represent substantial heterogeneity but also took into account the Chi<sup>2</sup> test (P &lt; 0.1) and direction of effects when making this judgement (<a href="./references#CD003919-bbs2-0119" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). </p> </section> <section id="CD003919-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>There were not enough trials/data on any single comparison to evaluate formally the possibility of publication bias with funnel plots. </p> </section> <section id="CD003919-sec-0036"> <h4 class="title">Data synthesis</h4> <p>The risk ratios from the individual trials were combined through meta‐analysis. We used a random‐effects model unless there were fewer than three trials in a comparison when we used a fixed‐effect model.  We did not pool studies if we judged that there was substantial heterogeneity (I<sup>2  </sup>of 50% or greater with a Chi<sup>2</sup> test P value less than 0.1 or different direction of effects).  </p> </section> <section id="CD003919-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We undertook subgroup analyses of the different technologies used ‐ argon laser, selective laser. Other planned subgroup analyses were not done because of lack of data (<a href="#CD003919-sec-0141">Differences between protocol and review</a>). </p> </section> <section id="CD003919-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>In modification to our protocol (<a href="#CD003919-sec-0141">Differences between protocol and review</a>), we performed a sensitivity analysis to check how robust the findings were given that some data were reported without correct adjustment for within‐person correlation (clustered studies where one or both eyes were included in the analysis) and some within‐person studies were not reported in accordance with their paired design.   </p> </section> <section id="CD003919-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We included a summary of findings table summarising absolute and relative effects. We considered the following comparisons: laser trabeculoplasty versus medication and laser trabeculoplasty versus trabeculectomy. </p> <p>We included the following outcomes: </p> <p> <ul id="CD003919-list-0007"> <li> <p>failure to control IOP (as defined by study investigators);</p> </li> <li> <p>failure to stabilise visual field progression (as defined by study investigators);</p> </li> <li> <p>failure to stabilise optic neuropathy progression (as defined by study investigators);</p> </li> <li> <p>quality of life measures, as available in the trial reports;</p> </li> <li> <p>adverse effects: PAS formation;</p> </li> <li> <p>adverse effects: IOP spikes;</p> </li> <li> <p>costs.</p> </li> </ul> </p> <p>We included data reported at the 24‐month time point, where possible. If those data were not available, we reported data at the nearest time point. </p> <p>Two authors (CRM and JE working together) graded the certainty of the evidence for each outcome using the GRADE approach (<a href="./references#CD003919-bbs2-0121" title="GRADEpro GDT. Version accessed 28 March 2022. Hamilton (ON): McMasters University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003919-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003919-sec-0040"></div> <section id="CD003919-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD003919-sec-0042"> <h4 class="title">Results of the search</h4> <p>The previous edition of this review (published in 2007) included 19 studies. </p> <p>The original scope of this review has since changed to include participants with ocular hypertension; see <a href="#CD003919-sec-0141">Differences between protocol and review</a>. Therefore, the searches were edited and re‐run on all databases for all years, and two previously excluded studies were included (<a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>; <a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>).   </p> <p>The searches were last updated on 28 October 2021. The re‐run of the searches generated a total of 4257 records (<a href="#CD003919-fig-0001">Figure 1</a>). After the removal of 2110 duplicates, the Cochrane Information Specialist screened the remaining 2147 records and removed 1350 references that were not relevant to the scope of the review. We screened the remaining 794 references and obtained 86 full‐text reports for further assessment. We included 31 reports of 20 new studies and have identified 10 ongoing studies and will assess these for potential inclusion when data become available. See <a href="./references#CD003919-sec-0146" title="">Characteristics of ongoing studies</a> for details. There are also six studies that are awaiting classification, see <a href="./references#CD003919-sec-0145" title="">Characteristics of studies awaiting classification</a> for details of follow‐up with the authors of these studies. </p> <div class="figure" id="CD003919-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Prisma flow diagram" data-id="CD003919-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Prisma flow diagram</p> </div> </div> </div> <p>In total, this review now contains 40 included studies and 59 excluded studies.</p> <p>We excluded <a href="./references#CD003919-bbs2-0053" title="BengtssonB , LeskeMC , YangZ , HeijlA , EMGT Group. Disc hemorrhages and treatment in the early manifest glaucoma trial. Ophthalmology2008;115(11):2044-8. HeijlA , LeskeMC , BengtssonB , BengtssonB , HusseinM , Early Manifest Glaucoma Trial Group. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmologica Scandinavia2003;81(3):286-93. HeijlA , LeskeMC , BengtssonB , HymanL , BengtssonB , HusseinM , Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression - results from Early Manifest Glaucoma Trial. Archives of Ophthalmology2002;120(10):1268-79. HymanL , KomaroffE , HeijlA , BengtssonB , LeskeMC , Early Manifest Glaucoma Trial Group. Treatment and vision-related quality of life in Early Manifest Glaucoma Trial. Ophthalmology2005;112(9):1505-13. LeskeMC , HeijlA , HusseinM , BengtssonB , HymanL , KomaroffE , et al. Factors for glaucoma progression and the effect of treatment - the Early Manifest Glaucoma Trial. Archives of Ophthalmology2003;121(1):48-56. LeskeMC , HeijlA , HymanL , BengtssonB , KomaroffE . Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Current Opinion in Ophthalmology2004;15(2):102-6. LeskeMC , HeijlA , HymanL , BengtssonB . Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology1999;106(11):2144-53. ">EMGT 1999</a> which was included in the previous edition of this review: we considered the comparison not eligible for inclusion because laser trabeculoplasty was combined with medication and compared to no treatment.  </p> </section> <section id="CD003919-sec-0043"> <h4 class="title">Included studies</h4> <section id="CD003919-sec-0044"> <h5 class="title">Types of participants</h5> <p>The 40 studies randomised 5613 eyes of 4028 participants (<a href="#CD003919-tbl-0003">Table 1</a>). These studies were conducted in the European region (19 studies), region of the Americas (13 studies), Western Pacific Region (6 studies) and  African region (1 study, Tanzania). One further study was conducted in 15 sites in Australia, New Zealand, Singapore, and UK. </p> <div class="table" id="CD003919-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>People</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Eyes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Average age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Age range</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% female</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% black</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Clustered (one or two eyes) or paired (within‐person) design</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>591</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>789</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 to 80</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58 to 73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweden</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norway</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 to 89</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 to 67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0011" title="BelkinM , GeffenN , OfirS , MessasAK , BarkanaY , BelkinA , et al. Direct Trans-scleral Selective laser Trabeculoplasty (SLT) without a gonioscopy lens. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 819. GeffenN , OfirS , BelkinA , SegevF , BarkanaY , MessasAK , et al. Transscleral selective laser trabeculoplasty without gonioscopy lens. Journal of Glaucoma2017;26(3):201-7. ">Geffen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Israel</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 to 80</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia, New Zealand, Singapore, UK (15 sites)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77% Caucasian 20% Asian</p> <p>3% other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0014" title="GoldenfeldM , MelamedS , SimonG , SimonGJB . Titanium: sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open angle glaucoma. Ophthalmic Surgery, Laser and Imaging2009;40(3):264-9. ">Goldenfeld 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Israel</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 to 91</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0015" title="GraysonD , RitchR , CamrasC , LustgartenJ , PodosS . Influence of treatment protocol on the long-term efficacy of argon laser trabeculoplasty. Journal of Glaucoma1993;2(7):7-12. LustgartenJ , PodosSM , RitchR , FischerR , StetzD , ZborowskiL , et al. Laser trabeculoplasty. A prospective study of treatment variables. Archives of Ophthalmology1984;102(4):517-9. ">Grayson 1993</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 to 92</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0016" title="GraysonD , ChiT , LiebmannJ , RitchR . Initial argon laser trabeculoplasty to the inferior vs superior half of trabecular meshwork. Archives of Ophthalmology1994;112(4):446-7. ">Grayson 1994</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0017" title="HugkulstoneCE . Argon laser trabeculoplasty with standard and long duration. Acta Ophthalmologica1990;68(5):579-81. HugkulstoneCE . Two-year follow-up of intra-ocular pressure control with long duration argon laser trabeculoplasty. Ophthalmologica1993;71(3):327-31. ">Hugkulstone 1990</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0020" title="KentSS , HutnikCM , BirtCM , DamjiKF , HarasymowyczP , SiF , et al. A randomized clinical trial of selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with pseudoexfoliation. Journal of Glaucoma2015;24(5):344-7. ">Kent 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tanzania</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>201</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>382</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>718</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1235</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 to 60 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Switzerland</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 to 73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0027" title="MoriartyBJ , CharJN , AchesonRW , DunnDT . Argon laser trabeculoplasty in primary open-angle glaucoma - results in black Jamaican population. International Ophthalmology1988;12(4):217-21. ">Moriarty 1988</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jamaica</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 to 77</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 to 90</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0030" title="RosenfeldE , ShemeshG , KurtzS . The efficacy of selective laser trabeculoplasty versus argon laser trabeculoplasty in pseudophakic glaucoma patients. Clinical Ophthalmology2012;6:1935-40. [DOI: 10.2147/OPTH.S34193]">Rosenfeld 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Israel</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0031" title="RouhiainenHJ , TerasvirtaME , TuovinenEJ . Peripheral anterior synechiae formation after trabeculoplasty. Archives of Ophthalmology1988;106(2):189-91. RouhiainenHJ , TerasvirtaME , TuovinenEJ . The effect of some treatment variables on the results of trabeculoplasty. Archives of Ophthalmology1988;106(5):611-3. ">Rouhiainen 1988</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finland</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51 to 87</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 to 90</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0033" title="SmithJ . Argon laser trabeculoplasty: comparison of bichromatic and monochromatic wavelengths. Ophthalmology1984;91(4):355-60. ">Smith 1984</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0034" title="TangM , FuY , FuMS , FanY , ZouHD , SunXD , et al. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surgery, Lasers and Imaging2011;42(1):59-63. [DOI: http://dx.doi.org/10.3928/15428877-20101124-07]TangM , FuY , MaY , FuM , FanY , SunX , et al. The efficacy of low-energy selective laser trabeculoplasty. Chinese Journal of Ophthalmology2011;47(10):887-92. ">Tang 2011</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 to 79</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0035" title="TufanAK , OnurIU , YiğitFU , AğaçhanA , NacaSA . Selective laser trabeculoplasty vs. fixed combinations with timolol in practice: a replacement study in primary open angle glaucoma. Turkish Journal of Ophthalmology2017;47:198-204. ">Tufan  2017</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38  to 86</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China (Hong Kong)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malaysia</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 to 81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70% Chinese, 30% Malay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0039" title="ZhangH , YangY , XuJ , YuM . A prospective randomized study of selective laser trabeculoplasty (SLT) as a replacement for medial therapy in primary open angle glaucoma. Zhonghua Yan Ke Za Zhi2015;51(2):109-14. ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selctive laser trabeculoplasty in primary patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. [DOI: 10.1155/2016/2153723]">Zhang 2015</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 to 72</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0040" title="ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selective laser trabeculoplasty in patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. ">Zhang 2016</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median: 67</p> <p>Min: 45</p> <p>Max: 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall range: 18 to 92 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median: 52</p> <p>Min: 13</p> <p>Max: 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> </div> <p>The average age of participants in the included studies ranged from 45 years to 75 years and the median average age was 67 years. In the individual studies, participants ranged in age from 18 to 92 years. The percentage of female participants ranged from 13% to 70% with a median value of 52%. Thirteen studies reported the ethnicity of participants and the percentage of people who were black or of African heritage ranged from 0% (<a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; <a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a>; <a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>; <a href="./references#CD003919-bbs2-0033" title="SmithJ . Argon laser trabeculoplasty: comparison of bichromatic and monochromatic wavelengths. Ophthalmology1984;91(4):355-60. ">Smith 1984</a>) to 100% (<a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>; <a href="./references#CD003919-bbs2-0027" title="MoriartyBJ , CharJN , AchesonRW , DunnDT . Argon laser trabeculoplasty in primary open-angle glaucoma - results in black Jamaican population. International Ophthalmology1988;12(4):217-21. ">Moriarty 1988</a>). Five studies were from China (<a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>; <a href="./references#CD003919-bbs2-0034" title="TangM , FuY , FuMS , FanY , ZouHD , SunXD , et al. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surgery, Lasers and Imaging2011;42(1):59-63. [DOI: http://dx.doi.org/10.3928/15428877-20101124-07]TangM , FuY , MaY , FuM , FanY , SunX , et al. The efficacy of low-energy selective laser trabeculoplasty. Chinese Journal of Ophthalmology2011;47(10):887-92. ">Tang 2011</a>; <a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a>; <a href="./references#CD003919-bbs2-0039" title="ZhangH , YangY , XuJ , YuM . A prospective randomized study of selective laser trabeculoplasty (SLT) as a replacement for medial therapy in primary open angle glaucoma. Zhonghua Yan Ke Za Zhi2015;51(2):109-14. ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selctive laser trabeculoplasty in primary patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. [DOI: 10.1155/2016/2153723]">Zhang 2015</a>; <a href="./references#CD003919-bbs2-0040" title="ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selective laser trabeculoplasty in patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. ">Zhang 2016</a>). </p> <p>All of the participants had OAG or OHT. The majority of participants in these trials had POAG but some had pseudoexfoliation (PXF) glaucoma or pigment dispersion. There were two major groups of participants: people who were newly diagnosed as glaucomatous or having OHT who needed initial therapy; and people who already had glaucoma or OHT diagnosed but showed signs of progression even with the use of maximal antihypertensive medical therapy. </p> </section> <section id="CD003919-sec-0045"> <h5 class="title">Types of interventions</h5> <p>Argon laser trabeculoplasty was mainly performed with blue‐green (488 and 514 nm) continuous <i>wave argon laser</i>, with a 50 micron spot size, 50 to 100 burns, with 0.8 to 2.0 watts, and 0.1 second exposure. Selective laser trabeculoplasty was mainly performed with a Nd:Yag laser, applied in non‐overlapping shots of a preset 3 nanoseconds duration and a preset 400 μm spot size  with the laser energy varying from 0.3 mJ to 1.4 mJ by the clinician using any laser gonioscopy lens. The desired endpoint was the production of a few fine ‘champagne bubbles’. </p> <p>Laser trabeculoplasty was compared with medication in 14 studies (<a href="#CD003919-tbl-0004">Table 2</a>) and with trabeculectomy in three studies (<a href="#CD003919-tbl-0005">Table 3</a>). Thirteen studies compared different lasers (<a href="#CD003919-tbl-0006">Table 4</a>). A further 10 studies compared different modifications of the laser technique (<a href="#CD003919-tbl-0007">Table 5</a>).  </p> <div class="table" id="CD003919-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Studies comparing laser trabeculoplasty with medication</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of uncontrolled IOP</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pilocarpine 4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP &gt; 26 mmHg or clinically evident visual field decay</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Timolol 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or greater</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG or PXF, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostaglandin analogue eye drop (latanoprost<br/>0.005%, travoprost 0.004%, bimatoprost 0.03% or tafluprost 0.0015%). If the IOP was not sufficiently well‐controlled, a stepped regimen of topical medications was followed which included the addition of beta‐adrenergic antagonists, alpha agonists and carbonic anhydrase inhibitors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less than or equal to 10% IOP reduction since baseline </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Timolol 0.5%</p> <p>Step 1: 0.5% timolol, twice a day<br/>Step 2: 0.1% dipivefrin, twice a day </p> <p>Step 3: Low‐dose pilocarpine, four times a day<br/>Step 4: High‐dose pilocarpine, four times a day<br/>Step 5: 0.5% timolol, twice a day with high dose pilocarpine, four times a day<br/>Step 6: 0.1% dipivefrin, twice a day with high dose pilocarpine, four times a day<br/>Step 7: Release from stepped regimen; treatment at discretion of GLT ophthalmologist </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or more</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG or OHT, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>timolol or<br/>betaxolol<br/>Step 3: Brimonidine<br/>Step 4: Dorzolamide, brinzolamide or a fixed‐combination<br/>dorzolamide‐timolol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Target IOP was determined using the Collaborative Initial Glaucoma Treatment Study<br/>formula. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG or OHT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Timolol 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP below or equal to target pressure according to glaucoma severity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG or OHT, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>β‐blocker, pilocarpine, dorzolamide and latanoprost either as monotherapy or in combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 21 mmHg on maximal therapy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG or OHT, newly diagnosed<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT followed by topical medication as required<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mainstream topical IOP‐lowering medication<br/>Medication classes for first‐, second‐ or third‐line treatment as per NICE1 European Glaucoma Society guidance: </p> <p>first‐line: prostaglandin analogue<br/>second‐line: beta‐blocker (alone or in combination with prostaglandin analogue combination)<br/>third‐ or fourth‐line: topical carbonic anhydrase inhibitor or alpha‐adrenoceptor agonist.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not defined<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG but unclear if newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pilocarpine and/or a sympathomimetic and/or timolol as initial therapy, increasing to maximum‐tolerated medical therapy which could require up to three topical medications and a carbonic anhydrase inhibitor </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or greater</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0027" title="MoriartyBJ , CharJN , AchesonRW , DunnDT . Argon laser trabeculoplasty in primary open-angle glaucoma - results in black Jamaican population. International Ophthalmology1988;12(4):217-21. ">Moriarty 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, on maximum medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT and medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pilocarpine 4% and acetazolamide 250mg four times a day. Four participants used timolol 0.5%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or greater</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG or OHT newly diagnosed or controlled on medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Latanaprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not defined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, on maximum medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum medical therapy (not specified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drop of IOP of less than 20% or IOP reading 22mmHg or greater</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0035" title="TufanAK , OnurIU , YiğitFU , AğaçhanA , NacaSA . Selective laser trabeculoplasty vs. fixed combinations with timolol in practice: a replacement study in primary open angle glaucoma. Turkish Journal of Ophthalmology2017;47:198-204. ">Tufan  2017</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed combinations: timolol maleate 0.5%, bimatoprost 0.03%, travoprost 0.004%, and latanoprost 0.005%, or timolol maleate 0.5%, dorzolamide hydrochloride 2%, brinzolamide 1%, and brimonidine tartrate 0.2% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Not defined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Current medications. Quote "Patients in the MED group were advised to step‐up their topical anti‐glaucoma medications by adding another topical anti‐glaucoma medication group until achieving target IOP. The step‐up regimen was following the sequence of adding first prostaglandin group, followed by β‐blocker, α2‐agonist, and carbonic anhydrase inhibitor." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not defined</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ALT: argon laser trabeculoplasty<br/>GLT: Glaucoma Laser Trial<br/>IOP: intraocular pressure<br/>MED: medication<br/>OAG: primary or secondary open‐angle glaucoma<br/>OHT: ocular hypertension<br/>POAG: primary open‐angle glaucoma<br/>PXF: pseudoexfoliation glaucoma<br/>SLT: selective laser trabeculoplasty </p> </div> </div> <div class="table" id="CD003919-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Studies comparing laser trabeculoplasty with trabeculectomy</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trabeculectomy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of uncontrolled IOP</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trabeculectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant met criteria for a further glaucoma intervention.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG but unclear if newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trabeculectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or more</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard technique with a fornix based flap</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuous IOP only</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IOP: intraocular pressure<br/>OAG: primary or secondary open‐angle glaucoma<br/>POAG: primary open‐angle glaucoma </p> </div> </div> <div class="table" id="CD003919-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Studies comparing different lasers</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of uncontrolled IOP</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>uncontrolled OAG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>On maximally tolerated medical therapy with the need for additional IOP lowering. Proportion success defined as  &gt;= 3 mmHg IOP decrease or &gt;= 20.0% IOP decrease from baseline<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excimer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP less than 20% compared with baseline values or needing to increase the number of glaucoma medications from pretreatment level </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, uncontrolled on maximum medical dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or more</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, on maximum tolerated medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP less than 20% compared with baseline values or needing to increase the number of glaucoma medications from pretreatment level </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG, on maximum tolerated medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for trabeculectomy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG, uncontrolled on maximum medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less than 20% IOP reduction</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0014" title="GoldenfeldM , MelamedS , SimonG , SimonGJB . Titanium: sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open angle glaucoma. Ophthalmic Surgery, Laser and Imaging2009;40(3):264-9. ">Goldenfeld 2009</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG, uncontrolled IOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Titanium‐sapphire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Success: reduction in IOP to 18 mm Hg or less, or by 30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary OAG or OHT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Titanium‐sapphire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Success: IOP &lt; 21 mm Hg with &gt; 20% decrease in IOP as compared with baseline without the need for further glaucoma procedures </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0020" title="KentSS , HutnikCM , BirtCM , DamjiKF , HarasymowyczP , SiF , et al. A randomized clinical trial of selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with pseudoexfoliation. Journal of Glaucoma2015;24(5):344-7. ">Kent 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG or OHT due to pseudoexfoliation syndrome, medically uncontrolled IOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Success/failure not defined<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG</p> <p>uncontrolled on topical medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"A complete success was defined as sustaining an IOP decrease from a baseline of more than 20% or of 3 mm Hg or greater, without undergoing further laser or surgery." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG, uncontrolled on topical medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pattern scanning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 20% decrease in IOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0030" title="RosenfeldE , ShemeshG , KurtzS . The efficacy of selective laser trabeculoplasty versus argon laser trabeculoplasty in pseudophakic glaucoma patients. Clinical Ophthalmology2012;6:1935-40. [DOI: 10.2147/OPTH.S34193]">Rosenfeld 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, pseudoexfoliation glaucoma, pigmentary glaucoma, or ocular hypertension (OHT), uncontrolled on topical medication </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>decrease of &lt; 15% in IOP from baseline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG and OHT recently diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pattern scanning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 20% decrease in IOP</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ALT: argon laser trabeculoplasty<br/>IOP: intraocular pressure<br/>MLT: micropulse laser trabeculoplasty<br/>OAG: primary or secondary open‐angle glaucoma<br/>OHT: ocular hypertension<br/>POAG: primary open‐angle glaucoma<br/>SLT: selective laser trabeculoplasty<br/>  </p> </div> </div> <div class="table" id="CD003919-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Studies comparing modifications of laser trabeculoplasty technique or regimens</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Technique</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of uncontrolled IOP</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180º x 360º</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Newly diagnosed OAG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP &lt; 21 mmHg, VF deterioration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0011" title="BelkinM , GeffenN , OfirS , MessasAK , BarkanaY , BelkinA , et al. Direct Trans-scleral Selective laser Trabeculoplasty (SLT) without a gonioscopy lens. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 819. GeffenN , OfirS , BelkinA , SegevF , BarkanaY , MessasAK , et al. Transscleral selective laser trabeculoplasty without gonioscopy lens. Journal of Glaucoma2017;26(3):201-7. ">Geffen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transcleral x conventional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG and exfoliation uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP decrease &lt; 15%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0015" title="GraysonD , RitchR , CamrasC , LustgartenJ , PodosS . Influence of treatment protocol on the long-term efficacy of argon laser trabeculoplasty. Journal of Glaucoma1993;2(7):7-12. LustgartenJ , PodosSM , RitchR , FischerR , StetzD , ZborowskiL , et al. Laser trabeculoplasty. A prospective study of treatment variables. Archives of Ophthalmology1984;102(4):517-9. ">Grayson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180º x 360º</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG and exfoliation uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need of further intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0016" title="GraysonD , ChiT , LiebmannJ , RitchR . Initial argon laser trabeculoplasty to the inferior vs superior half of trabecular meshwork. Archives of Ophthalmology1994;112(4):446-7. ">Grayson 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>superior x inferior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG and exfoliation uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need of further intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0017" title="HugkulstoneCE . Argon laser trabeculoplasty with standard and long duration. Acta Ophthalmologica1990;68(5):579-81. HugkulstoneCE . Two-year follow-up of intra-ocular pressure control with long duration argon laser trabeculoplasty. Ophthalmologica1993;71(3):327-31. ">Hugkulstone 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1 sec x 0.2 sec</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, pigmentary glaucoma and exfoliation uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuous IOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180º x 360º</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bilateral POAG uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP decrease &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0031" title="RouhiainenHJ , TerasvirtaME , TuovinenEJ . Peripheral anterior synechiae formation after trabeculoplasty. Archives of Ophthalmology1988;106(2):189-91. RouhiainenHJ , TerasvirtaME , TuovinenEJ . The effect of some treatment variables on the results of trabeculoplasty. Archives of Ophthalmology1988;106(5):611-3. ">Rouhiainen 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different power levels (500 mW x 800 mW)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG and exfoliation uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP ≥ 21 mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0033" title="SmithJ . Argon laser trabeculoplasty: comparison of bichromatic and monochromatic wavelengths. Ophthalmology1984;91(4):355-60. ">Smith 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuous‐wave laser (green) x blue‐green continuous‐wave laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need of further intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0034" title="TangM , FuY , FuMS , FanY , ZouHD , SunXD , et al. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surgery, Lasers and Imaging2011;42(1):59-63. [DOI: http://dx.doi.org/10.3928/15428877-20101124-07]TangM , FuY , MaY , FuM , FanY , SunX , et al. The efficacy of low-energy selective laser trabeculoplasty. Chinese Journal of Ophthalmology2011;47(10):887-92. ">Tang 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low energy x normal energy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0039" title="ZhangH , YangY , XuJ , YuM . A prospective randomized study of selective laser trabeculoplasty (SLT) as a replacement for medial therapy in primary open angle glaucoma. Zhonghua Yan Ke Za Zhi2015;51(2):109-14. ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selctive laser trabeculoplasty in primary patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. [DOI: 10.1155/2016/2153723]">Zhang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low energy x normal energy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP changes, changes in types of medication use, intervention success, daytime IOP fluctuation and complications </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ALT: argon laser trabeculoplasty<br/>IOP: intraocular pressure<br/>mW: milliwatts<br/>OAG: primary or secondary open‐angle glaucoma<br/>OHT: ocular hypertension<br/>POAG: primary open‐angle glaucoma<br/>SLT: selective laser trabeculoplasty<br/>VF: visual field </p> </div> </div> </section> <section id="CD003919-sec-0046"> <h5 class="title">Types of outcomes</h5> <p>All included trials reported success rates with a minimum six‐month follow‐up. The exact definition of success varied across trials, but IOP at or below 21 mmHg with or without medication was an inclusive definition. Others used a 20% decrease from initial IOP as the primary outcome (<a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a>; <a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; <a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a>; <a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a>; <a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>; <a href="./references#CD003919-bbs2-0039" title="ZhangH , YangY , XuJ , YuM . A prospective randomized study of selective laser trabeculoplasty (SLT) as a replacement for medial therapy in primary open angle glaucoma. Zhonghua Yan Ke Za Zhi2015;51(2):109-14. ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selctive laser trabeculoplasty in primary patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. [DOI: 10.1155/2016/2153723]">Zhang 2015</a>) or 15% decrease (<a href="./references#CD003919-bbs2-0011" title="BelkinM , GeffenN , OfirS , MessasAK , BarkanaY , BelkinA , et al. Direct Trans-scleral Selective laser Trabeculoplasty (SLT) without a gonioscopy lens. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 819. GeffenN , OfirS , BelkinA , SegevF , BarkanaY , MessasAK , et al. Transscleral selective laser trabeculoplasty without gonioscopy lens. Journal of Glaucoma2017;26(3):201-7. ">Geffen 2017</a>). Some studies considered the need for filtering surgery as failure criteria (<a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a>; <a href="./references#CD003919-bbs2-0015" title="GraysonD , RitchR , CamrasC , LustgartenJ , PodosS . Influence of treatment protocol on the long-term efficacy of argon laser trabeculoplasty. Journal of Glaucoma1993;2(7):7-12. LustgartenJ , PodosSM , RitchR , FischerR , StetzD , ZborowskiL , et al. Laser trabeculoplasty. A prospective study of treatment variables. Archives of Ophthalmology1984;102(4):517-9. ">Grayson 1993</a>; <a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a>). In addition, glaucoma progression defined as progression of visual field parameters, optic disk deterioration, and visual acuity decay was considered as failure criteria for some trials (<a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>; <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>; <a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a>; <a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a>). Peripheral anterior synechiae formation was a complication that defined failure of the procedure in one of the trials (<a href="./references#CD003919-bbs2-0031" title="RouhiainenHJ , TerasvirtaME , TuovinenEJ . Peripheral anterior synechiae formation after trabeculoplasty. Archives of Ophthalmology1988;106(2):189-91. RouhiainenHJ , TerasvirtaME , TuovinenEJ . The effect of some treatment variables on the results of trabeculoplasty. Archives of Ophthalmology1988;106(5):611-3. ">Rouhiainen 1988</a>). Some trials (<a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a>; <a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; <a href="./references#CD003919-bbs2-0017" title="HugkulstoneCE . Argon laser trabeculoplasty with standard and long duration. Acta Ophthalmologica1990;68(5):579-81. HugkulstoneCE . Two-year follow-up of intra-ocular pressure control with long duration argon laser trabeculoplasty. Ophthalmologica1993;71(3):327-31. ">Hugkulstone 1990</a>; <a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>; <a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a>) reported the final mean and standard deviation of the IOP and others (<a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>) reported the mean change and the standard deviation of the IOP from entry. The higher the change from entry, the better the result was. Intraocular pressure spikes in the initial hours after laser trabeculoplasty (<a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; <a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a>; <a href="./references#CD003919-bbs2-0017" title="HugkulstoneCE . Argon laser trabeculoplasty with standard and long duration. Acta Ophthalmologica1990;68(5):579-81. HugkulstoneCE . Two-year follow-up of intra-ocular pressure control with long duration argon laser trabeculoplasty. Ophthalmologica1993;71(3):327-31. ">Hugkulstone 1990</a>), uveitis after laser treatment (<a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>), systemic adverse events and ocular adverse events (<a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a>), such as the need for cataract surgery, trabeculectomy or self‐reported eye conditions (reduction of visual acuity, floaters and conjunctivitis) were adverse events reported in some studies. </p> <p>Indexes of quality of life were also considered outcomes in some trials (<a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>; <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>; <a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a>). </p> <p>Corneal endothelial cell counting decrease was recently used as a secondary outcome in two studies (<a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a>; <a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a>). </p> </section> <section id="CD003919-sec-0047"> <h5 class="title">Study design</h5> <p>Nineteen studies enrolled one eye of each participant in the study, although only a minority of these studies indicated how the eye was selected: the worse eye (<a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; <a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>; <a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>; <a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a>), the right eye (<a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a>), the first eye treated (<a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a>), or alternate right/left eyes (<a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a>). Seven studies were within‐person RCTs with one eye randomly allocated to treatment and the other to control (or other treatment) (<a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a>; <a href="./references#CD003919-bbs2-0017" title="HugkulstoneCE . Argon laser trabeculoplasty with standard and long duration. Acta Ophthalmologica1990;68(5):579-81. HugkulstoneCE . Two-year follow-up of intra-ocular pressure control with long duration argon laser trabeculoplasty. Ophthalmologica1993;71(3):327-31. ">Hugkulstone 1990</a>; <a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>; <a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a>; <a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a>; <a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a>; <a href="./references#CD003919-bbs2-0040" title="ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selective laser trabeculoplasty in patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. ">Zhang 2016</a>). The remaining studies enrolled one or both eyes per person. Some studies randomised eyes to treatment (<a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a>; <a href="./references#CD003919-bbs2-0015" title="GraysonD , RitchR , CamrasC , LustgartenJ , PodosS . Influence of treatment protocol on the long-term efficacy of argon laser trabeculoplasty. Journal of Glaucoma1993;2(7):7-12. LustgartenJ , PodosSM , RitchR , FischerR , StetzD , ZborowskiL , et al. Laser trabeculoplasty. A prospective study of treatment variables. Archives of Ophthalmology1984;102(4):517-9. ">Grayson 1993</a>; <a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a>); some studies randomised people to treatment but, for participants with two eyes eligible, used a within‐person study approach (<a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a>; <a href="./references#CD003919-bbs2-0016" title="GraysonD , ChiT , LiebmannJ , RitchR . Initial argon laser trabeculoplasty to the inferior vs superior half of trabecular meshwork. Archives of Ophthalmology1994;112(4):446-7. ">Grayson 1994</a>; <a href="./references#CD003919-bbs2-0027" title="MoriartyBJ , CharJN , AchesonRW , DunnDT . Argon laser trabeculoplasty in primary open-angle glaucoma - results in black Jamaican population. International Ophthalmology1988;12(4):217-21. ">Moriarty 1988</a>); some studies randomised people to treatment and both eyes received the same treatment (<a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>; <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>) and, in some studies, it was not clear how they allocated people/eyes (<a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; <a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a>; <a href="./references#CD003919-bbs2-0031" title="RouhiainenHJ , TerasvirtaME , TuovinenEJ . Peripheral anterior synechiae formation after trabeculoplasty. Archives of Ophthalmology1988;106(2):189-91. RouhiainenHJ , TerasvirtaME , TuovinenEJ . The effect of some treatment variables on the results of trabeculoplasty. Archives of Ophthalmology1988;106(5):611-3. ">Rouhiainen 1988</a>; <a href="./references#CD003919-bbs2-0039" title="ZhangH , YangY , XuJ , YuM . A prospective randomized study of selective laser trabeculoplasty (SLT) as a replacement for medial therapy in primary open angle glaucoma. Zhonghua Yan Ke Za Zhi2015;51(2):109-14. ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selctive laser trabeculoplasty in primary patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. [DOI: 10.1155/2016/2153723]">Zhang 2015</a>). </p> <p>In <a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>, the analysis was done with and without adjusting for within‐person correlation and results were similar. None of the other studies took into account the study design when doing the analysis: within‐person studies did not do a matched analysis and studies that randomly allocated eyes to treatment independently of the person did not take into account within‐person correlation. </p> </section> </section> <section id="CD003919-sec-0048"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD003919-sec-0144" title="">Characteristics of excluded studies</a> for further details. We excluded 59 studies for the following reasons: </p> <p> <ul id="CD003919-list-0008"> <li> <p>not a randomised controlled trial (24 studies)</p> </li> <li> <p>reported follow‐up was less than six months (14 studies)</p> </li> <li> <p>comparison not relevant for this review (9 studies)</p> </li> <li> <p>review outcome not measured (3 studies)</p> </li> <li> <p>study probably not done, or terminated early (6 studies)</p> </li> <li> <p>participants previously treated with laser (2 studies)</p> </li> <li> <p>primary angle‐closure glaucoma (1 study)</p> </li> </ul> </p> </section> </section> <section id="CD003919-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>The following authors assessed risk of bias independently in pairs or checked the risk of bias assessments, or both (AP, DB, JE, ML, CRM). See <a href="#CD003919-fig-0002">Figure 2</a> and <a href="#CD003919-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD003919-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD003919-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD003919-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD003919-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD003919-sec-0050"> <h4 class="title">Allocation</h4> <p>We judged 15 studies to be at low risk of selection bias (see <a href="#CD003919-fig-0003">Figure 3</a>). In these studies, we considered that adequate methods were used to generate an unpredictable (random) sequence that was adequately concealed from people recruiting participants. The other included studies did not provide enough information to judge one or both of these domains properly.  </p> </section> <section id="CD003919-sec-0051"> <h4 class="title">Blinding</h4> <p>We judged only two studies at low risk of performance bias (<a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a>; <a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a>). Participants were randomly allocated to two types of laser and the study authors reported specifically that the participants were masked to treatment allocation. </p> <p>Twelve studies reported masking observers and we judged these studies likely to be low risk of detection bias (see <a href="#CD003919-fig-0003">Figure 3</a>). </p> <p>The remaining studies were largely judged at high risk of performance and detection bias although some studies did not report enough information to make this judgement. </p> </section> <section id="CD003919-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>We judged eight studies to be at high risk of attrition bias, largely due to high or uneven loss to follow‐up between groups, or both (see <a href="#CD003919-fig-0003">Figure 3</a>) and, in one study, people who developed IOP greater than 22 mmHg during follow‐up were excluded (<a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a>). In the remaining studies, often follow‐up was not clearly described. Only 16 studies had convincing descriptions of high follow‐up balanced between groups. </p> </section> <section id="CD003919-sec-0053"> <h4 class="title">Selective reporting</h4> <p>Selective reporting was difficult to judge for most studies due to lack of availability of either a protocol or clinical trials registry entry. The majority of RCTs were assessed as unclear for reporting bias, since the initial protocol was not clearly prespecified. There was some evidence of selective reporting from <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a> and <a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a> and, in three studies where it was clear, all prespecified outcomes had been reported (<a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a>; <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>; <a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a>), </p> </section> <section id="CD003919-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>None noted.</p> </section> </section> <section id="CD003919-sec-0055"> <h3 class="title" id="CD003919-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD003919-tbl-0001"><b>Summary of findings 1</b> Laser trabeculoplasty versus medication</a>; <a href="./full#CD003919-tbl-0002"><b>Summary of findings 2</b> Laser trabeculoplasty versus trabeculectomy</a> </p> <section id="CD003919-sec-0056"> <h4 class="title">Laser trabeculoplasty versus medication</h4> <p>Fourteen studies addressed this comparison. The studies are summarised in <a href="#CD003919-tbl-0004">Table 2</a>. Results at 24 months are presented in <a href="./full#CD003919-tbl-0001">summary of findings Table 1</a>, including GRADE assessment for that time point.  </p> <p>Eight of these 14 studies included participants with primary open‐angle glaucoma and six studies included participants with primary or secondary open‐angle glaucoma. Five of the studies also included people with ocular hypertension. In most studies, the glaucoma was newly diagnosed, or probably newly diagnosed, but three studies enrolled people whose IOP was uncontrolled on maximum medication and one study enrolled people who were either newly diagnosed or already controlled on medical therapy. </p> <p>Six studies considered argon laser and eight studies considered selective laser trabeculoplasty. In two studies, the laser was combined with medication. The medication used in the comparator group of these studies was heterogeneous including pilocarpine, timolol, and latanoprost. Several studies specified a stepped regimen. In one study, the medication used was not specified clearly but was the maximum that could be tolerated (<a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a>). In one study, various medications were used: β‐blocker, pilocarpine, dorzolamide, and latanoprost either as monotherapy or in combination (<a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>). The <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a> study investigated laser first followed by topical medication compared with topical medication first.  </p> <section id="CD003919-sec-0057"> <h5 class="title">Failure to control IOP</h5> <p>Studies reported failure to control IOP at:</p> <p> <ul id="CD003919-list-0009"> <li> <p>six months: <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>; <a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>; <a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a> (mean IOP only); </p> </li> <li> <p>12 months: <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; <a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>; <a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>; <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>; <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>; <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>; <a href="./references#CD003919-bbs2-0027" title="MoriartyBJ , CharJN , AchesonRW , DunnDT . Argon laser trabeculoplasty in primary open-angle glaucoma - results in black Jamaican population. International Ophthalmology1988;12(4):217-21. ">Moriarty 1988</a>; <a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>; <a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a>; </p> </li> <li> <p>24 months: <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; <a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>; <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>; </p> </li> <li> <p>36 months <a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a>; <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>; </p> </li> <li> <p>five years  <a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>; <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>. </p> </li> </ul> </p> <p>Different definitions of failure to control IOP were used:</p> <p> <ul id="CD003919-list-0010"> <li> <p>Cut‐point: 22 mmHg or greater: <a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>; <a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>; <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>; <a href="./references#CD003919-bbs2-0027" title="MoriartyBJ , CharJN , AchesonRW , DunnDT . Argon laser trabeculoplasty in primary open-angle glaucoma - results in black Jamaican population. International Ophthalmology1988;12(4):217-21. ">Moriarty 1988</a>; </p> </li> <li> <p>Relative to baseline IOP: less than 20% fall in IOP from baseline: <a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>; 25% or less fall in IOP: <a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; </p> </li> <li> <p>Combination of relative to baseline IOP and cut‐point: less than 20% fall or IOP 22 mmHg or greater: <a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a>: </p> </li> <li> <p>Cut‐point or visual field loss: 26 mmHg or greater or 'visual field decay': <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; </p> </li> <li> <p>Target IOP defined on the basis of baseline IOP and visual field score: <a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>, or severity: <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>: </p> </li> <li> <p>Mean IOP only reported <a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a>. </p> </li> </ul> </p> <p><b>Six months:</b> Different results were seen for the three studies reporting outcomes around six months (<a href="./references#CD003919-fig-0004" title="">Analysis 1.1</a>, I<sup>2</sup> = 97%). The studies of argon laser showed a reduction in risk of failure to control IOP when compared with medication (RR 0.57, 95% CI 0.25 to 1.27 (<a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>) and RR 0.08, 95% CI 0.04 to 0.16) (<a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>). The study of selective trabeculoplasty (<a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>) reported a similar risk of failure in people with OAG or OHT treated with selective laser compared with a stepped medical regimen (RR 1.04, 95% CI 0.74 to 1.47). <a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a> reported data for right and left eyes separately. We have used these data for both eyes as reported and have not adjusted for within‐person correlation. This means that the confidence interval will be narrower than it should be. <a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a> reported mean IOP at six months in a small sample of 17 patients only. Quote "Mean reduction of IOP was 4.30 ± 1.64 mmHg in the SLT group and 2.71 ± 2.56 mmHg in the MED group at six months which was not statistically significant (P = 0.14) between two groups." </p> <p><b>12 months:</b> There was considerable heterogeneity with effects ranging from an RR of 0.19 (<a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a>) to 1.77 (<a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>) (<a href="./references#CD003919-fig-0005" title="">Analysis 1.2</a>). Overall I<sup>2</sup> was 90%, suggesting that much of the observed variation was not due to chance effects. As for six months follow‐up, the effect with argon laser appeared to be stronger (RR 0.37, 95% CI 0.22 to 0.61; participants/eyes = 788; studies = 5) than with selective laser which showed comparable effects to medication (RR 1.15, 95% CI 0.67 to 1.97; participants/eyes = 1882; studies = 5) and the test for subgroup differences showed a difference between groups (P = 0.002).  </p> <p><b>24 months:</b> Three studies of argon laser and two studies of selective laser reported failure to control IOP at 24 months (<a href="./references#CD003919-fig-0006" title="">Analysis 1.3</a>). Again, there was considerable heterogeneity of effect. Risk ratios ranged from 0.43 in favour of laser trabeculoplasty to 1.87 in favour of medication. Studies of argon laser compared with medication were more likely to show a beneficial effect compared with studies of selective laser (test for interaction, P = 0.0001). We judged this to be low‐certainty evidence, downgrading for risk of bias as the studies were not masked and there was inconsistency due to unexplained heterogeneity.  </p> <p><b>36 months:</b> In the <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a> study, fewer eyes were not at target IOP at 36 months in the selective laser group compared with the medication group (<a href="./references#CD003919-fig-0007" title="">Analysis 1.4</a>) (RR 0.73, 95% CI 0.45 to 1.18; eyes = 1072). A different result was seen in <a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a> (argon laser) but the study was very small with only 21 participants so the effect was imprecisely measured (RR 1.32, 95% CI 0.58 to 3).   </p> <p><b>Five years:</b> The follow‐up in <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a> (argon laser) was extended for five years and, at this time point, the risk of uncontrolled IOP was greater in the laser trabeculoplasty group (RR 1.83) but the confidence interval ranged from 0.93 to 3.61, i.e. including no effect (<a href="./references#CD003919-fig-0008" title="">Analysis 1.5</a>). A different direction of effect was seen in <a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a> but again with wide confidence intervals compatible with both benefit and harm (selective laser, RR 0.63, 95% CI 0.24 to 1.64).  </p> </section> <section id="CD003919-sec-0058"> <h5 class="title">Failure to stabilise visual field progression</h5> <p>Four studies reported visual field progression at:</p> <p> <ul id="CD003919-list-0011"> <li> <p>12 months: <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>; </p> </li> <li> <p>24 months: <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>; </p> </li> <li> <p>48 months: <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>; </p> </li> <li> <p>five years: <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>. </p> </li> </ul> </p> <p>With regard to the visual field assessment methods, <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a> used Goldman manual perimetry and the field plots were evaluated in a masked fashion by two independent observers. In <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>, the visual field was tested with a Friedman Mark II tangent screen initially but was replaced after two years with the Humphrey field analyser using a threshold 24‐2 testing strategy. In <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>, an Octopus automated perimeter, models 201 or 2000 were used. in <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>, visual fields were measured using standard automated perimetry and a global progression rate was calculated for each eye; fast and moderate progression were considered failure to stabilise visual field progression.   </p> <p><b>12 months:</b> Different results were seen in the two studies of argon laser reporting this outcome at 12 months (<a href="./references#CD003919-fig-0009" title="">Analysis 1.6</a>). In <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>, there was a reduced risk of failure to stabilise visual field progression (RR 0.44, 95% CI 0.20 to 0.94) and, in <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>, laser trabeculoplasty and medication had similar results (RR 0.96, 95% CI 0.59 to 1.59).  </p> <p><b>24 months:</b> There was a reduced risk of visual field progression at two years of follow‐up (RR 0.70, 95% CI 0.42 to 1.16) in two studies but the confidence interval ranged from 0.42 to 1.16, i.e. including no effect (<a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>) (<a href="./references#CD003919-fig-0010" title="">Analysis 1.7</a>). We judged this to be moderate‐certainty evidence. We downgraded for risk of bias as the studies were not masked but we did not downgrade for imprecision partly because of additional confirmatory evidence from the <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a> study at 48 months (see below).  </p> <p><b>48 months:</b> In <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a> (selective laser), there was a reduced chance of visual field progression in the laser group (RR 0.65. 95% CI 0.52 to 0.81) (<a href="./references#CD003919-fig-0011" title="">Analysis 1.8</a>). </p> <p><b>Five years:</b> In <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>), there was no precisely reported dichotomous outcome indicating the relative risk of visual field deterioration in each group. But there was a statement that, in the medicine‐treated group, there was a greater risk of visual field deterioration when compared with participants in the argon laser‐treated group.  </p> </section> <section id="CD003919-sec-0059"> <h5 class="title">Failure to stabilise optic neuropathy progression</h5> <p>Three studies reported optic neuropathy progression, two argon laser studies at 24 months (<a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>) and one selective laser study at 36 months (<a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>).  </p> <p><b>24 months:</b> There was no evidence of a difference in the risk of progression of optic neuropathy at 24 months in <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a> (RR 1.00, 95% 0.47 to 2.12) but, in <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>, there was a reduced risk (RR 0.53, 95% CI 0.27 to 1.03). The pooled RR was 0.73 (95% CI 0.44 to 1.20, I<sup>2</sup> =37%) (<a href="./references#CD003919-fig-0012" title="">Analysis 1.9</a>). We judged this to be very low‐certainty evidence because of risk of bias, imprecision, and inconsistency.  </p> <p><b>36 months: </b>In the <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a> study, 2/605 eyes treated with selective laser had evidence of optic neuropathy progression at 36 months, compared with 3/621 eyes in the medication group (RR 0.68, 95% CI 0.11 to  4.08).  </p> </section> <section id="CD003919-sec-0060"> <h5 class="title">Quality of life measures</h5> <p>The <a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a> reported health‐related and glaucoma‐specific quality of life scores at 12 months and 24 months. There was little difference in scores on 12 domains of the GOAT (Glaucoma Outcomes Assessment Tool) with the exception of 'social well‐being' where SLT patients reported a greater improvement at 24 months (mean difference (MD) 0.28, 95% CI  0.03 to 0.53) but it was unclear if this difference was important to patients.  </p> <p><a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a> measured quality of life using EuroQol (EQ‐5D) 5 levels. At 36 months, average EQ‐5D score was 0.89 (standard deviation (SD) 0.18) in the selective laser trabeculoplasty group versus 0.90 (SD 0.16) in the medication group (MD 0.01, 95% CI –0.01 to 0.03; P = 0·23). Similar findings were seen at other time points.  </p> <p>We judged this to be moderate‐certainty evidence, downgrading for risk of bias only. </p> </section> <section id="CD003919-sec-0061"> <h5 class="title">Economic data </h5> <p><a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a> did an economic analysis over 36 months. The UK study considered ophthalmology costs and used a willingness‐to‐pay cut‐point of  £20,000 per quality‐adjusted‐life‐year gained. There was a strong probability (97%) that selective laser (as first‐line treatment) was more cost‐effective than topical medication (as first‐line treatment).  In a small study of  17 participants in Malaysia, the cost per  1mmHg reduction in IOP was 165% higher in SLT compared with medication groups.  </p> </section> <section id="CD003919-sec-0062"> <h5 class="title">Adverse effects</h5> <section id="CD003919-sec-0063"> <h6 class="title">Peripheral anterior synechiae (PAS) formation</h6> <p><a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a> and <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a> (argon laser) described this outcome. The risk of PAS formation was greater in the laser trabeculoplasty group (RR 11.74, 95% CI 5.94 to 23.22) (<a href="./references#CD003919-fig-0013" title="">Analysis 1.10</a>). Both studies used argon laser. Three studies of selective laser (<a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>; <a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>; <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>) reported no PAS.  </p> <p>We judged this to be low‐certainty evidence downgrading for risk of bias and inconsistency. </p> </section> <section id="CD003919-sec-0064"> <h6 class="title">IOP spikes</h6> <p>Five percent of eyes randomised to SLT (21/429) developed early IOP spikes and, obviously, there was no IOP spike reported in the medication group (430 eyes) (RR 14.31, CI 95% 2.75 to 74.33). Three studies contributed data; all used selective laser trabeculoplasty (<a href="./references#CD003919-fig-0014" title="">Analysis 1.11</a>).  </p> <p>We judged this to be low‐certainty evidence downgrading for risk of bias and indirectness.</p> </section> <section id="CD003919-sec-0065"> <h6 class="title">Other adverse effects</h6> <section id="CD003919-sec-0066"> <p><b>Systemic adverse effects</b></p> <p>An example is a decrease of 20% or more in the forced expiratory volume after a metacholine test. <a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a> presented the results of a trial in which a subclinical bronchial reactivity after treatment of glaucomatous participants with laser trabeculoplasty or timolol eye drops was analysed. At both periods, three and four years, there was a tendency of a reduced risk ratio in bronchial reactivity in the trabeculoplasty group, but the estimate was imprecise and compatible with no difference in risk except at three years when the difference was statistically significant.  </p> </section> </section> </section> </section> <section id="CD003919-sec-0067"> <h4 class="title">Laser trabeculoplasty versus trabeculectomy</h4> <p>Three trials compared the effectiveness of laser trabeculoplasty with trabeculectomy. The details of these trials are summarised in <a href="#CD003919-tbl-0005">Table 3</a> (<a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a>, <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>; <a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a>). All three studies enrolled participants with open‐angle glaucoma (primary or secondary) and used argon laser compared with trabeculectomy. Results at 24 months are presented in <a href="./full#CD003919-tbl-0001">summary of findings Table 1</a>, including GRADE assessment for that time point.  </p> <section id="CD003919-sec-0068"> <h5 class="title">Failure to control IOP</h5> <p>Since AGIS had a cross‐over design, we included the first intervention comparisons of <a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a> and considered failure when the participant met the criteria for re‐intervention because of uncontrolled IOP. This information was received after personal contact with the study coordinator. <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a> defined failure to control IOP as a value of 22 mmHg or greater. <a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a> only reported IOP as a continuous variable and so was not included in these analyses. </p> <p><b>Six months:</b> Failure to control IOP was more frequently observed in the laser trabeculoplasty group when compared with trabeculectomy at six months (RR 3.33, 95% CI 1.72 to 6.42) but this finding largely reflected the results from AGIS which provided over 95% of the evidence (<a href="./references#CD003919-fig-0015" title="">Analysis 2.1</a>). </p> <p><b>24 months:</b> Failure to control IOP was more frequently observed in the laser trabeculoplasty group when compared with trabeculectomy at two years (RR 2.12, 95% CI 1.44 to 3.11) (<a href="./references#CD003919-fig-0016" title="">Analysis 2.2</a>). There was heterogeneity in the comparison (I<sup>2</sup> = 68%) but both estimates of effect were in the same direction. We judged this to be low‐certainty evidence downgrading for risk of bias and inconsistency. </p> </section> <section id="CD003919-sec-0069"> <h5 class="title">Failure to stabilise visual field progression</h5> <p><a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a> reported the number of absolute defects detected in the visual fields obtained by Friedmann and Humphrey fields after five years of follow‐up. But these findings were not reported as failure criteria. Mean deterioration in field score (number of spots) was greater in the laser group (approximately 2.3 (SD 3.7), approximate data extracted from graphs) compared with reduction of an average of 0.8 spots (SD 3.8) in the surgery group (and assuming error bars were correctly labelled as standard errors of the mean). Regression analysis, however, suggested that this difference was not statistically significant. </p> </section> <section id="CD003919-sec-0070"> <h5 class="title">Failure to stabilise optic neuropathy progression</h5> <p>Although the optic disc was photographed yearly in <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a> and after six months in <a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a>, optic disc progression of structural damage was not reported and was not considered a failure criterion in these two studies. </p> </section> <section id="CD003919-sec-0071"> <h5 class="title">Adverse effects</h5> <p>These were not consistently reported by these three studies. In <a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a>, trabeculectomy was associated with an increased risk of cataract (RR 1.78, 95% CI 1.46 to 2.16). </p> </section> <section id="CD003919-sec-0072"> <h5 class="title">Outcomes not reported</h5> <p> <ul id="CD003919-list-0012"> <li> <p>quality of life;</p> </li> <li> <p>economic data.</p> </li> </ul> </p> </section> </section> <section id="CD003919-sec-0073"> <h4 class="title">Different types of laser trabeculoplasty compared with each other</h4> <p>Thirteen studies compared different types of laser (<a href="#CD003919-tbl-0006">Table 4</a>). Nine of the studies recruited people whose glaucoma was not controlled on topical medication; two studies did not specify this as an inclusion criterion (<a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a>; <a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a>). One study enrolled people with primary OAG or OH (<a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a>), three studies enrolled people with primary OAG only (<a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a>; <a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a>; <a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a>), three studies included people with primary or secondary glaucoma (<a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a>; <a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; <a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a>; <a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a>), one study enrolled patients with pseudoexfoliation syndrome only (<a href="./references#CD003919-bbs2-0020" title="KentSS , HutnikCM , BirtCM , DamjiKF , HarasymowyczP , SiF , et al. A randomized clinical trial of selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with pseudoexfoliation. Journal of Glaucoma2015;24(5):344-7. ">Kent 2013</a>), and two studies did not specify type of participants (<a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a>; <a href="./references#CD003919-bbs2-0014" title="GoldenfeldM , MelamedS , SimonG , SimonGJB . Titanium: sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open angle glaucoma. Ophthalmic Surgery, Laser and Imaging2009;40(3):264-9. ">Goldenfeld 2009</a>). </p> <p>Four studies compared selective laser with argon laser (<a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; <a href="./references#CD003919-bbs2-0020" title="KentSS , HutnikCM , BirtCM , DamjiKF , HarasymowyczP , SiF , et al. A randomized clinical trial of selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with pseudoexfoliation. Journal of Glaucoma2015;24(5):344-7. ">Kent 2013</a>; <a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a>; <a href="./references#CD003919-bbs2-0030" title="RosenfeldE , ShemeshG , KurtzS . The efficacy of selective laser trabeculoplasty versus argon laser trabeculoplasty in pseudophakic glaucoma patients. Clinical Ophthalmology2012;6:1935-40. [DOI: 10.2147/OPTH.S34193]">Rosenfeld 2012</a>) and three studies compared diode laser with argon laser (<a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a>; <a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a>; <a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a>). The remaining six studies compared different lasers to selective laser: these were excimer laser (<a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a>), pattern scanning laser (<a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a>, <a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a>), titanium‐sapphire (<a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a>; <a href="./references#CD003919-bbs2-0014" title="GoldenfeldM , MelamedS , SimonG , SimonGJB . Titanium: sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open angle glaucoma. Ophthalmic Surgery, Laser and Imaging2009;40(3):264-9. ">Goldenfeld 2009</a>), and micropulse (<a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a>). </p> <section id="CD003919-sec-0074"> <h5 class="title">Failure to control IOP</h5> <p>Different definitions of failure to control IOP were used.</p> <p> <ul id="CD003919-list-0013"> <li> <p>less than 20% IOP decrease from initial values (<a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a>; <a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; <a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a>; <a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a>; <a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a>); </p> </li> <li> <p>less than 20% IOP decrease from initial values or needing to increase the number of glaucoma medications (<a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a>; <a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a>); </p> </li> <li> <p>22 mmHg or more (<a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a>); </p> </li> <li> <p>need for trabeculectomy (<a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a>); </p> </li> <li> <p>IOP 22 mmHg or less than 20% decrease from baseline (<a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a>); </p> </li> <li> <p>IOP 18 mmHg or more or less than 30% IOP decrease from baseline (<a href="./references#CD003919-bbs2-0014" title="GoldenfeldM , MelamedS , SimonG , SimonGJB . Titanium: sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open angle glaucoma. Ophthalmic Surgery, Laser and Imaging2009;40(3):264-9. ">Goldenfeld 2009</a>); </p> </li> <li> <p>Less than 3 mmHg reduction (<a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a>). </p> </li> </ul> </p> <p><a href="#CD003919-tbl-0008">Table 6</a> shows the results of these studies with respect to failure to control IOP. There was no consistent pattern to suggest any particular laser was better than any other with respect to control of IOP. However, there were few studies available for each comparison and the studies were underpowered. </p> <div class="table" id="CD003919-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Studies comparing different lasers: failure to control IOP</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Diode</b> </p> <p><b>(3 studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Selective</b> </p> <p><b>(4 studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Titanium‐sapphire</b> </p> <p><b>(1 study)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Excimer</b> </p> <p><b>(1 study)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pattern scanning</b> </p> <p><b>(2 studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Titanium‐sapphire</b> </p> <p><b>(1 study)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Micropulse (1 study)</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Comparator: argon</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>                                Comparator: selective</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85</p> <p>(0.16 to 4.64)</p> <p>(1 study, n=50)</p> <p><a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 </p> <p>(0.44 to 2.29)</p> <p>(1 study, n=63)</p> <p><a href="./references#CD003919-bbs2-0020" title="KentSS , HutnikCM , BirtCM , DamjiKF , HarasymowyczP , SiF , et al. A randomized clinical trial of selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with pseudoexfoliation. Journal of Glaucoma2015;24(5):344-7. ">Kent 2013</a> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63% of the eyes were considered failures in PLT group and 74% in SLT group (p=0.09)</p> <p>(n=58)</p> <p> <a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Proportion success defined as  &gt;= 3 mmHg IOP decrease or &gt;= 20.0% IOP decrease from baseline: MLT 29.6% vs SLT 36.0% (P = 0.77). </p> <p>(n=38)</p> <p><a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73</p> <p>(0.26 to 2.11)</p> <p>(2 studies, n=70)</p> <p><a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a>; <a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25</p> <p>(0.84 to 1.84)</p> <p>(1 study, n = 153) </p> <p><a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a> </p> <p>0.39 </p> <p>(0.15 to 0.97) </p> <p>(1 study, n=33)</p> <p> <a href="./references#CD003919-bbs2-0030" title="RosenfeldE , ShemeshG , KurtzS . The efficacy of selective laser trabeculoplasty versus argon laser trabeculoplasty in pseudophakic glaucoma patients. Clinical Ophthalmology2012;6:1935-40. [DOI: 10.2147/OPTH.S34193]">Rosenfeld 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was a reduction of 8.3 mmHg (SD 2.7) in TLT group (n = 18) and 6.5 mmHg (SD 4.3) in the ALT group (n = 17).  </p> <p><a href="./references#CD003919-bbs2-0014" title="GoldenfeldM , MelamedS , SimonG , SimonGJB . Titanium: sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open angle glaucoma. Ophthalmic Surgery, Laser and Imaging2009;40(3):264-9. ">Goldenfeld 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>Failure rate of 74.6% in SLT group and 84.6% in PLT group (p=0.155) (n=132)</p> <p><a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Failure rates of 56% in TLT group and 39% in SLT group (p=0.11) (n=37). </p> <p><a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> <p>(0.35 to 1.94)</p> <p>(2 studies, n=90)</p> <p><a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a>; <a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01</p> <p>(0.76 to 1.33)</p> <p>(2 studies, n=97)</p> <p><a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; <a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The cumulative probability of complete success was 53% for excimer laser vs 40% for SLT  (p=0.35) (n=30) </p> <p><a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In <a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a>, at two years, rates increased to 78% in TLT and 54% in SLT (p=0.11) </p> <p>(n=37)</p> <p><a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a>  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion success at 12 months: <br/>MLT 37.0%, SLT 36.0% (P = 1.0)  </p> <p>(n=38)</p> <p><a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ALT: argon laser trabeculoplasty<br/>IOP: intraocular pressure<br/>MLT: micropulse laser trabeculoplasty<br/>NR: not reported<br/>PLT:  pattern‐scanning laser trabeculoplasty <br/>SD:  standard deviation<br/>SLT: selective laser trabeculoplasty<br/>TLT:  titanium‐sapphire laser trabeculoplasty </p> </div> </div> </section> <section id="CD003919-sec-0075"> <h5 class="title">Adverse effects</h5> <p><a href="#CD003919-tbl-0009">Table 7</a> shows the adverse effects in these studies. </p> <div class="table" id="CD003919-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Studies comparing different lasers: adverse effects</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Argon laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Selective laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other lasers</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Micropulse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> "The MLT patients on average experienced less pain both during and after the treatment (P = 0.005)." "An IOP spike was defined as an elevation of.5 mmHg from the pretreatment mean. Incidence of post‐procedure spikes were 5.3% and 12.9% in the MLT and SLT groups, respectively, but this difference was not statistically significant (P = 0.4)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excimer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no difference in IOP spikes between the two groups of treatment (2/15 eyes in ELT versus 3/15 eyes in SLT group (RR 0.67, 95% CI 0.13 to 3.44). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP spikes: two eyes in each group had an increase of more than 5 mmHg after two hours postoperatively. </p> <p>PAS formation: Four eyes of the argon group developed PAS (RR 0.54; 95% CI 0.17 to 1.76). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP spikes: IOP after trabeculoplasty within two hours postoperatively and did not observe any IOP elevation greater than 5 mmHg in either group. </p> <p>PAS formation: no goniosynechiae formation was observed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP spikes: an increase in IOP from baseline of 2 to 6 mmHg in the first hour postoperatively in two eyes of the diode group and five eyes in the argon laser group. After 24 hours from the laser procedures in both groups, no eye experienced elevated IOP greater than 3 mmHg from baseline. </p> <p>PAS formation: <a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a>: some eyes presented at three months with synechiae. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical examination for flare and cells was assessed one hour post‐laser and graded on a scale from 0 (no reaction) to 4 (very marked reaction). There was no difference observed in mean score of flare in anterior chamber between the eyes treated with SLT (1.00, SD 0.6) and eyes treated with laser trabeculoplasty (0.8 SD 0.6). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0014" title="GoldenfeldM , MelamedS , SimonG , SimonGJB . Titanium: sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open angle glaucoma. Ophthalmic Surgery, Laser and Imaging2009;40(3):264-9. ">Goldenfeld 2009</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Titanium‐sapphire<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two patients (1 in each group) had trabeculectomy. Three cases of peripheral anterior synechiae in the ALT group but none in the TLT group.   </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Titanium‐sapphire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP spikes: Three participants in each group experienced spikes &gt; 10 mmHg, but two participants (11%) in TLT maintained an uncontrolled IOP and needed filtering surgeries. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0020" title="KentSS , HutnikCM , BirtCM , DamjiKF , HarasymowyczP , SiF , et al. A randomized clinical trial of selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with pseudoexfoliation. Journal of Glaucoma2015;24(5):344-7. ">Kent 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No IOP spikes in either group (pressure difference of 6 or more after 1 hour)<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pattern scanning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP spikes: One patient in SLT group, had a spike of 15 mmHG, and needed a filtering surgery. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0030" title="RosenfeldE , ShemeshG , KurtzS . The efficacy of selective laser trabeculoplasty versus argon laser trabeculoplasty in pseudophakic glaucoma patients. Clinical Ophthalmology2012;6:1935-40. [DOI: 10.2147/OPTH.S34193]">Rosenfeld 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pattern scanning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One patient in PLT group developed a protracted uveitis, that resolved with topical steroids after 6 months. One subject in SLT and one in PLT group had IOP spike in the first day (&gt; 20% IOP). One patient in PLT developed cataracts and one in SLT developed angle closure, and needed an iridotomy. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ALT: argon laser trabeculoplasty<br/>ELT: excimer laser trabeculoplasty<br/>IOP: intraocular pressure<br/>MLT: micropulse laser trabeculoplasty<br/>OAG: primary or secondary open‐angle glaucoma<br/>OHT: ocular hypertension<br/>PLT: pattern scanning laser trabeculoplasty<br/>POAG primary open‐angle glaucoma<br/>SD: standard deviation<br/>SLT: selective laser trabeculoplasty<br/>TLT: titanium‐sapphire laser trabeculoplasty </p> </div> </div> </section> <section id="CD003919-sec-0076"> <h5 class="title">Outcomes not reported</h5> <p>None of the twelve studies reported any of the following outcomes:</p> <p> <ul id="CD003919-list-0014"> <li> <p>failure to stabilise visual field progression;</p> </li> <li> <p>failure to stabilise optic neuropathy progression;</p> </li> <li> <p>quality of life;</p> </li> <li> <p>economic data.</p> </li> </ul> </p> <p><a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a> reported that visual field mean deviation, average retinal nerve fibre layer (RNFL) thickness, corneal endothelial cell counts and visual acuity were similar between the treatment groups (pattern scanning laser trabeculoplasty (PLT) and SLT) at 12 months.  </p> </section> </section> <section id="CD003919-sec-0077"> <h4 class="title">Modifications of laser trabeculoplasty technique or regimens</h4> <p>Ten studies compared different techniques of laser trabeculoplasty (<a href="#CD003919-tbl-0007">Table 5</a>), six using argon laser trabeculoplasty (<a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a>; <a href="./references#CD003919-bbs2-0015" title="GraysonD , RitchR , CamrasC , LustgartenJ , PodosS . Influence of treatment protocol on the long-term efficacy of argon laser trabeculoplasty. Journal of Glaucoma1993;2(7):7-12. LustgartenJ , PodosSM , RitchR , FischerR , StetzD , ZborowskiL , et al. Laser trabeculoplasty. A prospective study of treatment variables. Archives of Ophthalmology1984;102(4):517-9. ">Grayson 1993</a>; <a href="./references#CD003919-bbs2-0016" title="GraysonD , ChiT , LiebmannJ , RitchR . Initial argon laser trabeculoplasty to the inferior vs superior half of trabecular meshwork. Archives of Ophthalmology1994;112(4):446-7. ">Grayson 1994</a>; <a href="./references#CD003919-bbs2-0017" title="HugkulstoneCE . Argon laser trabeculoplasty with standard and long duration. Acta Ophthalmologica1990;68(5):579-81. HugkulstoneCE . Two-year follow-up of intra-ocular pressure control with long duration argon laser trabeculoplasty. Ophthalmologica1993;71(3):327-31. ">Hugkulstone 1990</a>; <a href="./references#CD003919-bbs2-0031" title="RouhiainenHJ , TerasvirtaME , TuovinenEJ . Peripheral anterior synechiae formation after trabeculoplasty. Archives of Ophthalmology1988;106(2):189-91. RouhiainenHJ , TerasvirtaME , TuovinenEJ . The effect of some treatment variables on the results of trabeculoplasty. Archives of Ophthalmology1988;106(5):611-3. ">Rouhiainen 1988</a>; <a href="./references#CD003919-bbs2-0033" title="SmithJ . Argon laser trabeculoplasty: comparison of bichromatic and monochromatic wavelengths. Ophthalmology1984;91(4):355-60. ">Smith 1984</a>) and four using selective laser trabeculoplasty (<a href="./references#CD003919-bbs2-0011" title="BelkinM , GeffenN , OfirS , MessasAK , BarkanaY , BelkinA , et al. Direct Trans-scleral Selective laser Trabeculoplasty (SLT) without a gonioscopy lens. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 819. GeffenN , OfirS , BelkinA , SegevF , BarkanaY , MessasAK , et al. Transscleral selective laser trabeculoplasty without gonioscopy lens. Journal of Glaucoma2017;26(3):201-7. ">Geffen 2017</a>; <a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a>; <a href="./references#CD003919-bbs2-0034" title="TangM , FuY , FuMS , FanY , ZouHD , SunXD , et al. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surgery, Lasers and Imaging2011;42(1):59-63. [DOI: http://dx.doi.org/10.3928/15428877-20101124-07]TangM , FuY , MaY , FuM , FanY , SunX , et al. The efficacy of low-energy selective laser trabeculoplasty. Chinese Journal of Ophthalmology2011;47(10):887-92. ">Tang 2011</a>; <a href="./references#CD003919-bbs2-0039" title="ZhangH , YangY , XuJ , YuM . A prospective randomized study of selective laser trabeculoplasty (SLT) as a replacement for medial therapy in primary open angle glaucoma. Zhonghua Yan Ke Za Zhi2015;51(2):109-14. ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selctive laser trabeculoplasty in primary patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. [DOI: 10.1155/2016/2153723]">Zhang 2015</a>).  </p> <section id="CD003919-sec-0078"> <h5 class="title">Monochromatic wavelength trabeculoplasty versus bichromatic wavelength trabeculoplasty</h5> <p><a href="./references#CD003919-bbs2-0033" title="SmithJ . Argon laser trabeculoplasty: comparison of bichromatic and monochromatic wavelengths. Ophthalmology1984;91(4):355-60. ">Smith 1984</a> examined the effect of trabeculoplasty using a continuous‐wave laser (green) compared to the standard technology performed with the blue‐green continuous‐wave laser. </p> <section id="CD003919-sec-0079"> <h6 class="title">Failure to control IOP</h6> <p>Failure was defined as IOP at a level requiring any additional intervention to prevent glaucoma progression. There was no clear difference in the risk ratio of uncontrolled IOP between groups (RR 0.57, 95% CI 0.18 to 1.83). </p> </section> <section id="CD003919-sec-0080"> <h6 class="title">Adverse effects: PAS formation</h6> <p>There was no clear difference in the risk ratio of PAS formation between the two groups (RR 1.30, 95% CI 0.63 to 2.68). </p> </section> <section id="CD003919-sec-0081"> <h6 class="title">Outcomes not reported</h6> <p> <ul id="CD003919-list-0015"> <li> <p>Failure to control visual field progression;</p> </li> <li> <p>Failure to control optic neuropathy progression;</p> </li> <li> <p>Health‐related quality of life;</p> </li> <li> <p>Economic data.</p> </li> </ul> </p> </section> </section> <section id="CD003919-sec-0082"> <h5 class="title">Two‐stage trabeculoplasty versus one‐stage trabeculoplasty</h5> <p><a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a> analysed the effectiveness of laser trabeculoplasty performed in one session (one stage), treating 360 degrees of the angle and in two sessions, four weeks apart, treating 180 degrees of the angle in each session and reported risk of field progression and IOP spikes as outcomes. <a href="./references#CD003919-bbs2-0015" title="GraysonD , RitchR , CamrasC , LustgartenJ , PodosS . Influence of treatment protocol on the long-term efficacy of argon laser trabeculoplasty. Journal of Glaucoma1993;2(7):7-12. LustgartenJ , PodosSM , RitchR , FischerR , StetzD , ZborowskiL , et al. Laser trabeculoplasty. A prospective study of treatment variables. Archives of Ophthalmology1984;102(4):517-9. ">Grayson 1993</a> stratified eyes in three groups: group one was randomised to receive 100 burns over 360 degrees over the trabecular meshwork, group two received 50 burns over 180 degrees in two sessions and group three received 50 burns over 360 degrees also in two sessions. The primary outcome was the need for further intervention, an outcome not included in this review. At seven years follow‐up, there did appear to be a significant benefit of a two‐stage procedure. </p> <section id="CD003919-sec-0083"> <h6 class="title">Failure to stabilise visual field progression</h6> <p>In <a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a>, the relative risk of progression between the two groups was based on a few events making the estimate very imprecise (RR 3.3, 95% CI 0.14 to 76.46). </p> </section> <section id="CD003919-sec-0084"> <h6 class="title">Adverse effects: IOP spikes</h6> <p>We defined spikes as IOP elevations above 22 mmHg. In <a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a>, six eyes in the two stages group developed IOP elevation, while 11 eyes in the one‐stage group showed this increase. The confidence limit of the relative risk between these two groups (RR 0.60, 95% CI 0.28 to 1.31) was compatible with no difference. </p> </section> <section id="CD003919-sec-0085"> <h6 class="title">Outcomes not reported</h6> <p> <ul id="CD003919-list-0016"> <li> <p>Failure to control IOP;</p> </li> <li> <p>Failure to control optic neuropathy progression;</p> </li> <li> <p>Health‐related quality of life;</p> </li> <li> <p>Economic data.</p> </li> </ul> </p> </section> </section> <section id="CD003919-sec-0086"> <h5 class="title">Superior trabeculoplasty versus inferior trabeculoplasty</h5> <p>In <a href="./references#CD003919-bbs2-0016" title="GraysonD , ChiT , LiebmannJ , RitchR . Initial argon laser trabeculoplasty to the inferior vs superior half of trabecular meshwork. Archives of Ophthalmology1994;112(4):446-7. ">Grayson 1994</a>, the primary outcome was the need for further glaucoma surgery, which was not included as an outcome in this review. There was no difference at two years of follow‐up in the need for further surgery between the group in which the meshwork was treated superiorly (18/40) and the group treated inferiorly (23/53). </p> </section> <section id="CD003919-sec-0087"> <h5 class="title">Argon laser trabeculoplasty applied at different power levels</h5> <p><a href="./references#CD003919-bbs2-0031" title="RouhiainenHJ , TerasvirtaME , TuovinenEJ . Peripheral anterior synechiae formation after trabeculoplasty. Archives of Ophthalmology1988;106(2):189-91. RouhiainenHJ , TerasvirtaME , TuovinenEJ . The effect of some treatment variables on the results of trabeculoplasty. Archives of Ophthalmology1988;106(5):611-3. ">Rouhiainen 1988</a> is the only trial that compared different power levels for laser trabeculoplasty. Four groups were randomised to receive laser at 500 mW, 600 mW, 700 mW and 800 mW. We used 500 mW as the standard technique and compared the other three power levels with the first. The authors described an adverse effect as outcome (PAS formation). Effectiveness in controlling IOP, visual field decay, and optic nerve progression were unpublished data and no additional information was obtained from the authors. </p> <section id="CD003919-sec-0088"> <h6 class="title">Adverse effects: PAS formation</h6> <p>Two eyes of 29 randomised to 500 mW developed PAS formation at six months of follow‐up compared to eyes treated with 600 mW, in which 7/30 developed PAS (RR 3.38; 95% CI 0.77 to 14.96). When compared to eyes treated with 700 mW, of which 5/30 developed PAS, no significant difference was again observed (RR 2.42, 95% CI 0.51 to 11.48). But when eyes treated with 500 mW were compared to those treated with 800 mW, there was an increased risk of synechiae formation in the latter (12/30 developed PAS) (RR 5.80, 95% CI 1.42 to 23.69). </p> </section> <section id="CD003919-sec-0089"> <h6 class="title">Outcomes not reported</h6> <p> <ul id="CD003919-list-0017"> <li> <p>Failure to control IOP;</p> </li> <li> <p>Failure to control visual field progression;</p> </li> <li> <p>Failure to control optic neuropathy progression;</p> </li> <li> <p>Health‐related quality of life;</p> </li> <li> <p>Economic data.</p> </li> </ul> </p> </section> </section> <section id="CD003919-sec-0090"> <h5 class="title">Argon laser trabeculoplasty using 0.1 seconds versus 0.2 seconds</h5> <p>Time of exposure, a parameter used during laser trabeculoplasty, was analysed in <a href="./references#CD003919-bbs2-0017" title="HugkulstoneCE . Argon laser trabeculoplasty with standard and long duration. Acta Ophthalmologica1990;68(5):579-81. HugkulstoneCE . Two-year follow-up of intra-ocular pressure control with long duration argon laser trabeculoplasty. Ophthalmologica1993;71(3):327-31. ">Hugkulstone 1990</a>. The study used 0.1 seconds versus 0.2 seconds time exposure laser in a within‐person design. Outcomes described were mean IOP at six, 12 and 18 months (outcomes not included in this review), and the presence of IOP spikes at one hour. Intraocular pressures were marginally but not significantly lower in the participants with longer treatment duration. </p> <section id="CD003919-sec-0091"> <h6 class="title">Adverse effects: Intraocular pressure spikes at one hour</h6> <p>At one hour of follow‐up, 7/33 eyes treated with energy delivered at 0.1 seconds and 10/33 eyes treated with 0.2 seconds developed an increase of 10 mmHg or more. The confidence limits around the estimated difference in risk (RR 0.70, 95% CI 0.30 to 1.62) are compatible with no difference. </p> </section> <section id="CD003919-sec-0092"> <h6 class="title">Outcomes not reported</h6> <p> <ul id="CD003919-list-0018"> <li> <p>Failure to control IOP;</p> </li> <li> <p>Failure to control visual field progression;</p> </li> <li> <p>Failure to control optic neuropathy progression;</p> </li> <li> <p>Health‐related quality of life;</p> </li> <li> <p>Economic data.</p> </li> </ul> </p> </section> </section> <section id="CD003919-sec-0093"> <h5 class="title">Low energy selective laser trabeculoplasty versus normal energy laser trabeculoplasty</h5> <section id="CD003919-sec-0094"> <h6 class="title">Failure to control IOP</h6> <p>Two trials described this outcome (<a href="./references#CD003919-bbs2-0034" title="TangM , FuY , FuMS , FanY , ZouHD , SunXD , et al. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surgery, Lasers and Imaging2011;42(1):59-63. [DOI: http://dx.doi.org/10.3928/15428877-20101124-07]TangM , FuY , MaY , FuM , FanY , SunX , et al. The efficacy of low-energy selective laser trabeculoplasty. Chinese Journal of Ophthalmology2011;47(10):887-92. ">Tang 2011</a>; <a href="./references#CD003919-bbs2-0039" title="ZhangH , YangY , XuJ , YuM . A prospective randomized study of selective laser trabeculoplasty (SLT) as a replacement for medial therapy in primary open angle glaucoma. Zhonghua Yan Ke Za Zhi2015;51(2):109-14. ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selctive laser trabeculoplasty in primary patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. [DOI: 10.1155/2016/2153723]">Zhang 2015</a>). In <a href="./references#CD003919-bbs2-0034" title="TangM , FuY , FuMS , FanY , ZouHD , SunXD , et al. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surgery, Lasers and Imaging2011;42(1):59-63. [DOI: http://dx.doi.org/10.3928/15428877-20101124-07]TangM , FuY , MaY , FuM , FanY , SunX , et al. The efficacy of low-energy selective laser trabeculoplasty. Chinese Journal of Ophthalmology2011;47(10):887-92. ">Tang 2011</a>, at 12 months of follow‐up 20/39 eyes that received low energy trabeculoplasty developed uncontrolled IOP at 24 months of follow‐up and 18/35 eyes that were submitted to normal energy laser trabeculoplasty had uncontrolled IOP, suggesting no difference but with a wide confidence interval. In <a href="./references#CD003919-bbs2-0039" title="ZhangH , YangY , XuJ , YuM . A prospective randomized study of selective laser trabeculoplasty (SLT) as a replacement for medial therapy in primary open angle glaucoma. Zhonghua Yan Ke Za Zhi2015;51(2):109-14. ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selctive laser trabeculoplasty in primary patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. [DOI: 10.1155/2016/2153723]">Zhang 2015</a> at 12 months, 6/26 eyes randomised to conventional SLT had uncontrolled IOP, while 5/26 of the eyes that received low energy SLT, had the same outcome. </p> </section> <section id="CD003919-sec-0095"> <h6 class="title">Adverse effects: IOP spikes</h6> <p>IOP spikes were significantly more frequent in the normal energy group (10/39 eyes in low energy and 24/35 eyes in normal energy group (RR 0.37 95% CI 0.21 to 0.67) in <a href="./references#CD003919-bbs2-0034" title="TangM , FuY , FuMS , FanY , ZouHD , SunXD , et al. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surgery, Lasers and Imaging2011;42(1):59-63. [DOI: http://dx.doi.org/10.3928/15428877-20101124-07]TangM , FuY , MaY , FuM , FanY , SunX , et al. The efficacy of low-energy selective laser trabeculoplasty. Chinese Journal of Ophthalmology2011;47(10):887-92. ">Tang 2011</a>. </p> </section> <section id="CD003919-sec-0096"> <h6 class="title">Outcomes not reported</h6> <p> <ul id="CD003919-list-0019"> <li> <p>Failure to control visual field progression</p> </li> <li> <p>Failure to control optic neuropathy progression</p> </li> <li> <p>Health‐related quality of life</p> </li> <li> <p>Economic data</p> </li> </ul> </p> </section> </section> <section id="CD003919-sec-0097"> <h5 class="title">Trans‐scleral laser trabeculoplasty without a goniolens versus conventional SLT</h5> <section id="CD003919-sec-0098"> <h6 class="title">Failure to control IOP</h6> <p><a href="./references#CD003919-bbs2-0011" title="BelkinM , GeffenN , OfirS , MessasAK , BarkanaY , BelkinA , et al. Direct Trans-scleral Selective laser Trabeculoplasty (SLT) without a gonioscopy lens. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 819. GeffenN , OfirS , BelkinA , SegevF , BarkanaY , MessasAK , et al. Transscleral selective laser trabeculoplasty without gonioscopy lens. Journal of Glaucoma2017;26(3):201-7. ">Geffen 2017</a> noted that 2/14 participants in the new technique failed in the 6th postoperative period (14.3%), while 5/14 (35.7%) did the same in the conventional SLT technique at this follow‐up period. </p> </section> <section id="CD003919-sec-0099"> <h6 class="title">Adverse effects: IOP spikes</h6> <p>IOP spikes were found in 1/14 eyes in trans‐scleral SLT and 4/14 eyes in conventional SLT. </p> </section> <section id="CD003919-sec-0100"> <h6 class="title">Outcomes not reported</h6> <p> <ul id="CD003919-list-0020"> <li> <p>Failure to control visual field progression;</p> </li> <li> <p>Failure to control optic neuropathy progression;</p> </li> <li> <p>Health‐related quality of life;</p> </li> <li> <p>Economic data.</p> </li> </ul> </p> </section> </section> <section id="CD003919-sec-0101"> <h5 class="title">180º selective laser trabeculoplasty versus 360º selective trabeculoplasty</h5> <section id="CD003919-sec-0102"> <h6 class="title">Failure to control IOP</h6> <p><a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a> described at six months, a failure rate in decreasing IOP 20% or more in 27% of eyes that received 180º SLT and in 23% of eyes receiving 360º SLT.  </p> </section> <section id="CD003919-sec-0103"> <h6 class="title">Adverse effects: IOP spikes</h6> <p>Two eyes of the same participant developed a non‐persistent 3 mmHg IOP increase when receiving 180º in one eye and 360º in the other eye. </p> </section> <section id="CD003919-sec-0104"> <h6 class="title">Outcomes not reported</h6> <p> <ul id="CD003919-list-0021"> <li> <p>Failure to control visual field progression;</p> </li> <li> <p>Failure to control optic neuropathy progression;</p> </li> <li> <p>Health‐related quality of life;</p> </li> <li> <p>Economic data.</p> </li> </ul> </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003919-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003919-sec-0105"></div> <section id="CD003919-sec-0106"> <h3 class="title" id="CD003919-sec-0106">Summary of main results</h3> <p>We included 40 studies (5613 eyes of 4028 people) in this review. The majority of the studies were conducted in Europe and in the USA. Most of the studies were at risk of performance and/or detection bias as they were unmasked. None of the studies were judged as having low risk of bias for all domains. We did not identify any studies of laser trabeculoplasty alone versus no intervention. </p> <section id="CD003919-sec-0107"> <h4 class="title">Laser trabeculoplasty versus medication</h4> <p>Fourteen studies compared laser trabeculoplasty with medication in either people with primary OAG (7 studies), or primary or secondary OAG (7 studies); five of the 14 studies also included participants with OHT. Six studies used argon laser trabeculoplasty and eight studies used selective laser trabeculoplasty. There was considerable clinical and methodological diversity in these studies leading to statistical heterogeneity in results for the primary outcome "failure to control IOP" at 24 months. Risk ratios (RR) ranged from 0.43 in favour of laser trabeculoplasty to 1.87 in favour of medication (5 studies, I<sup>2</sup> = 89%). Studies of argon laser compared with medication were more likely to show a beneficial effect compared with studies of selective laser (test for interaction P = 0.0001) but the argon laser studies were older and the medication comparator group in those studies may have been less effective. We considered this to be low‐certainty evidence because the trials were at risk of bias (they were not masked) and there was unexplained heterogeneity. There was evidence from two studies (624 eyes) that argon laser treatment was associated with less failure to stabilise visual field progression compared with medication (RR 0.70, 95% CI 0.42 to 1.16) at 24 months and one further study of selective laser also reported a reduced risk at 48 months (RR 0.65, 95% CI 0.52 to 0.81, 1178 eyes). We judged this moderate‐certainty evidence downgrading for risk of bias. There was only very low‐certainty evidence on optic neuropathy progression. Adverse effects were more commonly seen in the laser trabeculoplasty group including peripheral anterior synechiae (PAS) associated with argon laser (RR 11.15, 95% CI 5.63 to 22.09; 624 eyes; 2 RCTs; low‐certainty evidence); 5% of participants treated with laser in three studies of selective laser group had early IOP spikes (moderate‐certainty evidence). One UK‐based study provided moderate‐certainty evidence that laser trabeculoplasty was more cost‐effective.  </p> </section> <section id="CD003919-sec-0108"> <h4 class="title">Laser trabeculoplasty versus trabeculectomy</h4> <p>Three studies compared laser trabeculoplasty with trabeculectomy. All three studies enrolled participants with OAG (primary or secondary) and used argon laser. People receiving laser trabeculoplasty may have a higher risk of uncontrolled IOP at 24 months compared with people receiving trabeculectomy (RR 2.12, 95% CI 1.44 to 3.11; 901 eyes; 2 RCTs). We judged this to be low‐certainty evidence because of risk of bias (trials were not masked) and there was inconsistency between the two trials (I<sup>2</sup> = 68%). There was limited evidence on visual field progression suggesting a higher risk of failure with laser trabeculoplasty. There was no information on optic neuropathy progression, quality of life, or costs. PAS formation and IOP spikes were not reported but in one study trabeculectomy was associated with an increased risk of cataract (RR 1.78, 95% CI 1.46 to 2.16) (very low‐certainty evidence). </p> </section> <section id="CD003919-sec-0109"> <h4 class="title">Comparison of different laser trabeculoplasty technologies</h4> <p>Thirteen studies compared different types of laser; six of these studies recruited patients whose glaucoma was not controlled on topical medication. Participants had primary OAG (6 studies) or primary or secondary OAG (4 studies). Three of these studies included people with OHT. The following comparisons were made: selective versus argon laser (4 studies); diode versus argon laser (3 studies); pattern scanning (2 studies), excimer (1 study), micropulse (1 study) or titanium‐sapphire (1 study) versus selective laser and titanium‐sapphire versus argon laser (1 study). There was no consistent pattern to suggest any particular laser was better than any other with respect to control of IOP. However, there were few studies available for each comparison and the studies were underpowered. Ten studies compared different protocols of laser trabeculoplasty and, in general, there were no clear differences observed. Again, the studies were underpowered. Power levels above 800 mW in ALT seemed to have an increased risk of PAS at six months of follow‐up compared to eyes that received 500 mW ALT (RR 5.80, 95% CI 1.42 to 23.69, 30 eyes, 1 RCT). </p> </section> </section> <section id="CD003919-sec-0110"> <h3 class="title" id="CD003919-sec-0110">Overall completeness and applicability of evidence</h3> <p>Laser trabeculoplasty and its role in OAG and OHT management is still controversial and there is much variation in practice. This review included evidence of the effects of laser trabeculoplasty as a first intervention and in participants already using maximal medical tolerated therapy. It included trials published in the last 30 years during which period there have been numerous developments in glaucoma management. Topical carbonic anhydrase inhibitors, alpha‐agonists, and prostaglandin analogues were introduced after 1990. The trials comparing medication and ALT were usually designed before this decade (<a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>; <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>; <a href="./references#CD003919-bbs2-0027" title="MoriartyBJ , CharJN , AchesonRW , DunnDT . Argon laser trabeculoplasty in primary open-angle glaucoma - results in black Jamaican population. International Ophthalmology1988;12(4):217-21. ">Moriarty 1988</a>; <a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a>). Incisional surgery has also changed in the past few decades. There is evidence showing that antimetabolites are useful in achieving consistent low intraocular pressure in filtering surgery for glaucoma (<a href="./references#CD003919-bbs2-0116" title="CabourneE , ClarkeJC , SchlottmannPG , EvansJR . Mitomycin C versus 5-fluorouracil for wound healing in glaucoma surgery. Cochrane Database of Systematic Reviews2015 , Issue 11. Art. No: CD006259. [DOI: 10.1002/14651858.CD006259.pub2]">Cabourne 2015</a>). Trials comparing trabeculoplasty and trabeculectomy were designed before the 1990s and antimetabolites were not used in these studies (<a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>; <a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a>). In <a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a>, 205 eyes of 378 treated initially with trabeculectomy were operated on after 1990 and probably augmented with 5‐fluorouracil or mitomycin C. </p> <p>In the current update (2021), we have included trials that compared the effects of SLT and medication (<a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; <a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>; <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>; <a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>; <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>; <a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>; <a href="./references#CD003919-bbs2-0035" title="TufanAK , OnurIU , YiğitFU , AğaçhanA , NacaSA . Selective laser trabeculoplasty vs. fixed combinations with timolol in practice: a replacement study in primary open angle glaucoma. Turkish Journal of Ophthalmology2017;47:198-204. ">Tufan  2017</a>; <a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a>). SLT has been largely used to control IOP in OAG and OHT in the last decade, and many papers have been published since this technique was described. More recently, SLT is being recommended as first‐line therapy for OAG and OHT and, with these new studies, some conclusions could have been drawn to analyse the position of SLT in the glaucoma treatment scale.   </p> <p>The main outcomes in this review were uncontrolled IOP and glaucoma progression, detected by progressive visual field damage and progressive optic neuropathy. Unfortunately, few trials had documented the latter two outcomes, and some of them had such a short follow‐up (six months) that it would probably not be possible to detect progression. Trials with shorter follow‐up and without detection of glaucomatous neuropathy progression were included, not only because they met the inclusion criteria but also because maintaining IOP control even in the short term may result in less discomfort, inconvenience, and costs for patients. The concept of target IOP, which defines failure in IOP control, has also evolved over this period. <a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a> was one of the trials that concluded that a group of glaucomatous participants had an increased risk of progression when their IOP was consistently over 18 mmHg. In the majority of trials, uncontrolled IOP was considered to be consistently greater than 22 mmHg (<a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a>; <a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>; <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>; <a href="./references#CD003919-bbs2-0027" title="MoriartyBJ , CharJN , AchesonRW , DunnDT . Argon laser trabeculoplasty in primary open-angle glaucoma - results in black Jamaican population. International Ophthalmology1988;12(4):217-21. ">Moriarty 1988</a>; <a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a>). Even in <a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a>, failure was determined when IOP was higher than 22 mmHg for certain groups. <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a> considered failure as daily curves of IOP that had measurements over 26 mmHg. Other trials defined failure as the need for further surgical intervention (which was usually linked to uncontrolled IOP) (<a href="./references#CD003919-bbs2-0015" title="GraysonD , RitchR , CamrasC , LustgartenJ , PodosS . Influence of treatment protocol on the long-term efficacy of argon laser trabeculoplasty. Journal of Glaucoma1993;2(7):7-12. LustgartenJ , PodosSM , RitchR , FischerR , StetzD , ZborowskiL , et al. Laser trabeculoplasty. A prospective study of treatment variables. Archives of Ophthalmology1984;102(4):517-9. ">Grayson 1993</a>; <a href="./references#CD003919-bbs2-0033" title="SmithJ . Argon laser trabeculoplasty: comparison of bichromatic and monochromatic wavelengths. Ophthalmology1984;91(4):355-60. ">Smith 1984</a>; <a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a>)) or reducing IOP to less than 20% of initial values (<a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a>; <a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>). </p> <p>Visual field testing has also changed in the past few decades. Because of this and inherent long‐term fluctuation in test performance, it was difficult to standardise visual field progression as an outcome. In the current update, more consistent information regarding visual field progression has been described, especially in the <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a> trial. </p> <p>It is interesting that in <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a> there was an improvement in the results of visual field after randomisation in both groups, suggesting a learning effect common in this kind of psychophysical analysis, but which could also lead to erroneous conclusions. Another consideration is that there is much heterogeneity in the instruments for visual field analysis. In <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>, Goldman manual perimetry was used and the plotted charts were evaluated in a masked fashion by two independent observers. In <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a>, visual field was tested with a Friedman Mark III analyser initially and after two years, a Humphrey field analyser was used. In <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>, the Octopus automated perimeter models 201 or 2000, were used. </p> <p>Health‐related quality of life is also an important outcome; <a href="./references#CD003919-bbs2-0053" title="BengtssonB , LeskeMC , YangZ , HeijlA , EMGT Group. Disc hemorrhages and treatment in the early manifest glaucoma trial. Ophthalmology2008;115(11):2044-8. HeijlA , LeskeMC , BengtssonB , BengtssonB , HusseinM , Early Manifest Glaucoma Trial Group. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmologica Scandinavia2003;81(3):286-93. HeijlA , LeskeMC , BengtssonB , HymanL , BengtssonB , HusseinM , Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression - results from Early Manifest Glaucoma Trial. Archives of Ophthalmology2002;120(10):1268-79. HymanL , KomaroffE , HeijlA , BengtssonB , LeskeMC , Early Manifest Glaucoma Trial Group. Treatment and vision-related quality of life in Early Manifest Glaucoma Trial. Ophthalmology2005;112(9):1505-13. LeskeMC , HeijlA , HusseinM , BengtssonB , HymanL , KomaroffE , et al. Factors for glaucoma progression and the effect of treatment - the Early Manifest Glaucoma Trial. Archives of Ophthalmology2003;121(1):48-56. LeskeMC , HeijlA , HymanL , BengtssonB , KomaroffE . Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Current Opinion in Ophthalmology2004;15(2):102-6. LeskeMC , HeijlA , HymanL , BengtssonB . Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology1999;106(11):2144-53. ">EMGT 1999</a> was one of the studies that potentially attempted to estimate it, but it was excluded in this version (<a href="#CD003919-sec-0141">Differences between protocol and review</a>). <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>; <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>; <a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; and <a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a> used quality of life as one of the main outcomes of the trials. There were no significant differences between different questionnaires in the two groups, except for Glaucoma Assessment Tools (assessed in one trial), in which the trabeculoplasty group seemed to have a better result than medication. </p> <p>There was limited evidence on cost‐effectiveness and this was in a high‐income setting (UK), as reported in <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>.   </p> <p>Secondary outcomes were related to adverse effects and were: PAS formation, early IOP spikes, especially when different laser trabeculoplasty techniques were compared (<a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a>; <a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a>; <a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a>; <a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; <a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a>; <a href="./references#CD003919-bbs2-0017" title="HugkulstoneCE . Argon laser trabeculoplasty with standard and long duration. Acta Ophthalmologica1990;68(5):579-81. HugkulstoneCE . Two-year follow-up of intra-ocular pressure control with long duration argon laser trabeculoplasty. Ophthalmologica1993;71(3):327-31. ">Hugkulstone 1990</a>; <a href="./references#CD003919-bbs2-0031" title="RouhiainenHJ , TerasvirtaME , TuovinenEJ . Peripheral anterior synechiae formation after trabeculoplasty. Archives of Ophthalmology1988;106(2):189-91. RouhiainenHJ , TerasvirtaME , TuovinenEJ . The effect of some treatment variables on the results of trabeculoplasty. Archives of Ophthalmology1988;106(5):611-3. ">Rouhiainen 1988</a>; <a href="./references#CD003919-bbs2-0033" title="SmithJ . Argon laser trabeculoplasty: comparison of bichromatic and monochromatic wavelengths. Ophthalmology1984;91(4):355-60. ">Smith 1984</a>), uveitis (<a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>), and ocular and general side effects (<a href="./references#CD003919-bbs2-0059" title="GandolfiSA , SangermaniC , CiminoL , UngaroN , Tardini, ViswanathanA , et al. Is there a non IOP related effect of brimonidine on visual field progression in human glaucoma?Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 2298. ">Gandolfi 2004</a>). In the update, it was observed that decrease in endothelial cell count was a secondary outcome described in <a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a> and <a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a>, and also central corneal thickness was an outcome described in <a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a>. </p> <p>In terms of complications, not surprisingly ALT caused a higher risk of PAS formation when compared to medication. PAS formation is not a relevant adverse event observed in trials developed with SLT. Considering systemic side effects, the risk of topical beta‐blocker‐induced bronchospasm after a metacholine test, when compared to laser trabeculoplasty in asymptomatic participants, was not statistically significant except at three years (<a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a>). Although this study was considered of good methodological quality, it was the only trial to examine this outcome and was small and probably lacked power to detect small risk effects. </p> <p><a href="./references#CD003919-bbs2-0027" title="MoriartyBJ , CharJN , AchesonRW , DunnDT . Argon laser trabeculoplasty in primary open-angle glaucoma - results in black Jamaican population. International Ophthalmology1988;12(4):217-21. ">Moriarty 1988</a> and <a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a> evaluated outcomes in participants already on maximally tolerated medical anti‐glaucoma therapy. Argon laser trabeculoplasty decreased the risk of uncontrolled IOP but there was considerable heterogeneity between the two trials. Racial differences and severity of glaucoma could explain the observed heterogeneity. We did not include these trials in the analysis, because the design of the studies was clearly different. They included uncontrolled participants on maximal medical therapy and randomised half of the participants to ALT, keeping the other participants on observation, despite being out of control. We did not include these studies because of lack of external validity. </p> <p>We also studied trials that included SLT compared to medication in participants with OAG or OHT. With regard to the effectiveness of SLT when compared to medication, we did not observe differences in risk of uncontrolled IOP (low‐certainty) in people on SLT compared with those on medication (<a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>, <a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>), and a stepped regimen in (<a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>; <a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>), nor in naive subjects as seen in <a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>; <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>. Data were available at 12, 24 and 36 months follow‐up and significant heterogeneity between the comparisons was seen. With a moderate degree of certainty, it was observed that SLT decreased the risk of visual field progression at 15 years of follow‐up (<a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>). Health‐related quality of life was reported in some trials (<a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>; <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a> and <a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a>). There were no significant differences in relative risks between different questionnaires, in the two groups, except for Glaucoma Assessment Tools (assessed in one trial), in which the trabeculoplasty group seemed to have a better result than medication. </p> <p><a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a>, <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a> and <a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a> all compared laser trabeculoplasty with trabeculectomy. At six months, there was a reduced relative risk of uncontrolled IOP for trabeculectomy (only in a few cases, mitomycin‐augmented) compared to laser trabeculoplasty. If this result was to be extrapolated to current glaucoma management, the difference in the risk of uncontrolled IOP would probably be more pronounced because antimetabolites are now used more often and achieve a greater reduction in IOP. We could not detect a difference between groups at 24 months because, in combining the studies for this comparison, heterogeneity was too high (we used both the random‐effects and fixed‐effect models). </p> <p>Considering different techniques for ALT, treating 360 degrees in one session or 180 degrees in two sessions did not affect the risk of progression of visual field loss after six months and did not increase the risk of postoperative IOP spikes (<a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a>). The sample size in this trial was small and further studies might help to confirm or refute these findings. The only factor that seemed to increase the risk of PAS formation was using higher power settings, such as 800 mW (<a href="./references#CD003919-bbs2-0031" title="RouhiainenHJ , TerasvirtaME , TuovinenEJ . Peripheral anterior synechiae formation after trabeculoplasty. Archives of Ophthalmology1988;106(2):189-91. RouhiainenHJ , TerasvirtaME , TuovinenEJ . The effect of some treatment variables on the results of trabeculoplasty. Archives of Ophthalmology1988;106(5):611-3. ">Rouhiainen 1988</a>). </p> <p>In terms of comparison of different laser technology, SLT was evaluated in one trial which did demonstrate similar efficacy when compared to ALT (<a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>). <a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a> and <a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a> showed that the chance of uncontrolled IOP was similar in participants treated with ALT or diode at six months and one year and two years. The risk of early IOP spikes and PAS formation were also similar in both groups. Finally, a monochromatic wave laser, manufactured by MIRA, was compared with the traditional bichromatic wavelength. There was no difference in the risk of uncontrolled IOP or of PAS formation. This laser was not approved by the Food and Drug Administration (FDA) and consequently not used in USA. </p> <p>Emerging technologies have been developed to be applied to people with OAG and OHT, and some trials compare their efficacy to SLT which is increasingly considered to be the standard form of trabeculoplasty. <a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a> with excimer laser trabeculoplasty (ELT), <a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a> with titanium laser trabeculoplasty (TLT), <a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a> with micropulse diode laser trabeculoplasty (MLT) and <a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a> and <a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a> with PLT showed that, when compared to standard SLT, failure rates were very similar at six and 12 months of follow‐up, with similar adverse effects (rare IOP spikes). </p> <p>Also, variations in technique were studied with RCTs, such as applying SLT without a goniolens (<a href="./references#CD003919-bbs2-0011" title="BelkinM , GeffenN , OfirS , MessasAK , BarkanaY , BelkinA , et al. Direct Trans-scleral Selective laser Trabeculoplasty (SLT) without a gonioscopy lens. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 819. GeffenN , OfirS , BelkinA , SegevF , BarkanaY , MessasAK , et al. Transscleral selective laser trabeculoplasty without gonioscopy lens. Journal of Glaucoma2017;26(3):201-7. ">Geffen 2017</a>), only 180 degrees (<a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a>; <a href="./references#CD003919-bbs2-0035" title="TufanAK , OnurIU , YiğitFU , AğaçhanA , NacaSA . Selective laser trabeculoplasty vs. fixed combinations with timolol in practice: a replacement study in primary open angle glaucoma. Turkish Journal of Ophthalmology2017;47:198-204. ">Tufan  2017</a>) and decreasing the amount of energy (<a href="./references#CD003919-bbs2-0034" title="TangM , FuY , FuMS , FanY , ZouHD , SunXD , et al. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surgery, Lasers and Imaging2011;42(1):59-63. [DOI: http://dx.doi.org/10.3928/15428877-20101124-07]TangM , FuY , MaY , FuM , FanY , SunX , et al. The efficacy of low-energy selective laser trabeculoplasty. Chinese Journal of Ophthalmology2011;47(10):887-92. ">Tang 2011</a>; <a href="./references#CD003919-bbs2-0039" title="ZhangH , YangY , XuJ , YuM . A prospective randomized study of selective laser trabeculoplasty (SLT) as a replacement for medial therapy in primary open angle glaucoma. Zhonghua Yan Ke Za Zhi2015;51(2):109-14. ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selctive laser trabeculoplasty in primary patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. [DOI: 10.1155/2016/2153723]">Zhang 2015</a>). These techniques were compared to standard SLT. Once again, no major differences were observed in terms of uncontrolled IOP or adverse effects (IOP spikes) at six and 12 months of follow‐up but power to detect clinically relevant differences may have been limited. </p> </section> <section id="CD003919-sec-0111"> <h3 class="title" id="CD003919-sec-0111">Quality of the evidence</h3> <p>With regard to methodological quality, nine trials were considered of good quality in all criteria measured (<a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a>; <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>; <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a>; <a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>; <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>; <a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>; <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>; <a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a>; <a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a>).  </p> <p>The most important comparisons in this review were between laser trabeculoplasty and medication. <a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a>, <a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a> and <a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a> were trials that described the effect of ALT compared with medication in newly diagnosed participants. Evidence showing that, at 24 months, argon laser decreased the risk of uncontrolled IOP compared to medication was graded low‐certainty (downgraded for risk of bias) because trials were not masked and one trial was at risk of selective outcome reporting. In addition, the medical treatments used in these trials are not currently considered first‐line medication (downgraded for indirectness). </p> <p>From these trials based on very low grade of evidence, we concluded that there was no difference in the risk of decay of either visual field or optic disc when ALT was compared to medication in people with OAG at 24 months of follow‐up. Evidence was downgraded because trials were not masked and one trial was at risk of selective outcome reporting (downgraded for risk of bias). As before, because the medical treatment used in these trials was not contemporary, evidence was downgraded for indirectness and there were wide confidence intervals compatible with both benefit and harm for ALT compared to medication (downgraded for imprecision). </p> <p>When SLT and medication were compared for OAG and OHT (<a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; <a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a>; <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>; <a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a>; <a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a>; <a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>), we concluded that there was low‐grade evidence that both laser and current medical treatment to reduce IOP in OAG and OHT are similarly effective. Evidence was downgraded because none of the studies were masked, one study was at high risk of attrition bias (downgraded for risk of bias), there were wide confidence intervals compatible with both benefit and harm for SLT compared to medication (downgraded for imprecision), and there was also significant heterogeneity in the studies comparisons. On the other hand, there was moderate‐certainty evidence, provided by one trial, that the risk of visual field progression could be reduced by initiating treatment with SLT in OAG and OH. This effect was observed at five years of follow‐up. Depending on the health system, initiating treatment with SLT can be cost‐effective. </p> </section> <section id="CD003919-sec-0112"> <h3 class="title" id="CD003919-sec-0112">Potential biases in the review process</h3> <p>The main source of bias in this review is likely to be publication bias. There were insufficient studies in any single intervention comparison to allow for funnel plots and many studies may have been conducted before trial registration was a requirement or even since that time because many trials in ophthalmology still go unregistered. Different stages of OAG and different inclusion criteria (naive or medicated subjects) could also introduce a bias in comparisons in SLT trials. </p> <p>Some of the methods in the current update of the review were introduced since the last review: in particular, summary of findings tables. The choice of comparisons and outcomes for these tables therefore has the potential to be data‐driven as they were not prespecified in the protocol. Where possible, we have focussed on time points ‐ 24 months ‐ and outcomes relevant to patients. In fact, we were able to include most of our outcomes in the summary of findings table including a selection of adverse events. In the current update, it was possible to introduce relevant outcomes, such as quality of life results and economic evaluation data, that were not available in previous publications. </p> </section> <section id="CD003919-sec-0113"> <h3 class="title" id="CD003919-sec-0113">Agreements and disagreements with other studies or reviews</h3> <p>Two recent systematic reviews on laser trabeculoplasty have been published.</p> <p><a href="./references#CD003919-bbs2-0139" title=" ZhouR , SunY , ChenH , ShaS , HeM , WangW . Laser trabeculoplasty for open-angle glaucoma: a systematic review and network meta-analysis. American Journal of Ophthalmology2021;229:301-13. [DOI: 10.1016/j.ajo.2020.07.046]">Zhou 2021</a> compared the efficacy of laser trabeculoplasty with different modalities of treatment for OAG and OHT, but limited the search from 2000 to 2019. There were some differences in inclusion criteria to the current review ‐ they included people previously treated with laser and outcomes were restricted to IOP control at six and 12 months of follow‐up. The conclusions were similar to those obtained in the current review, but the grade of evidence was not clearly described. </p> <p><a href="./references#CD003919-bbs2-0117" title="ChiSC , KangYN , HwangDK , LiuCJ . Selective laser trabeculoplasty versus medication for open-angle glaucoma: systematic review and meta-analysis of randomised clinical trials. British Journal of Ophthalmology 2020;104(11):1500-7.">Chi 2020</a> focussed on selective laser trabeculoplasty. The authors included eight studies, five of which were also included in the current review. The three studies not included in the current review were either out of scope for the current review (laser trabeculoplasty as an adjunctive treatment  <a href="./references#CD003919-bbs2-0125" title="LeeJW , ChanCW , WongMO , Chan JCh, LiQ , LaiJS . A randomized control trial to evaluate the effect of adjuvant selective laser trabeculoplasty versus medication alone in primary open-angle glaucoma: preliminary results. Clinical Ophthalmology2014;8:1987-92. [DOI: 10.2147/OPTH.S70903]">Lee 2014</a>), reflected two publications considered in this review to be the same study (<a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a>) and one study was excluded from this review as being non‐random (<a href="./references#CD003919-bbs2-0049" title="De KeyserM , De BelderM , De BelderJ , GrootV . Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients. Acta Ophthalmologica2018;96(5):e577-e81. De KeyserM , De BelderM , De GrootV . Quality of life in glaucoma patients after selective laser trabeculoplasty. International Journal of Ophthalmology2017;10(5):742-8. ">De Keyser 2017</a>). The current review included three additional studies of selective laser trabeculoplasty published since <a href="./references#CD003919-bbs2-0117" title="ChiSC , KangYN , HwangDK , LiuCJ . Selective laser trabeculoplasty versus medication for open-angle glaucoma: systematic review and meta-analysis of randomised clinical trials. British Journal of Ophthalmology 2020;104(11):1500-7.">Chi 2020</a> was published (<a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a>; <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a>; <a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a>). The focus of the <a href="./references#CD003919-bbs2-0117" title="ChiSC , KangYN , HwangDK , LiuCJ . Selective laser trabeculoplasty versus medication for open-angle glaucoma: systematic review and meta-analysis of randomised clinical trials. British Journal of Ophthalmology 2020;104(11):1500-7.">Chi 2020</a> review on selective laser trabeculoplasty only and the fact that more recent studies such as <a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a> were not included meant there was less heterogeneity observed compared with the current review, however, overall the conclusions were similar.   </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003919-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Prisma flow diagram" data-id="CD003919-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Prisma flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD003919-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD003919-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laser trabeculoplasty versus medication, Outcome 1: Failure to control IOP at 6 months" data-id="CD003919-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Laser trabeculoplasty versus medication, Outcome 1: Failure to control IOP at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laser trabeculoplasty versus medication, Outcome 2: Failure to control IOP at 12 months" data-id="CD003919-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Laser trabeculoplasty versus medication, Outcome 2: Failure to control IOP at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laser trabeculoplasty versus medication, Outcome 3: Failure to control IOP at 24 months" data-id="CD003919-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Laser trabeculoplasty versus medication, Outcome 3: Failure to control IOP at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laser trabeculoplasty versus medication, Outcome 4: Failure to control IOP at 36 months" data-id="CD003919-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Laser trabeculoplasty versus medication, Outcome 4: Failure to control IOP at 36 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laser trabeculoplasty versus medication, Outcome 5: Failure to control IOP at 5 years" data-id="CD003919-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Laser trabeculoplasty versus medication, Outcome 5: Failure to control IOP at 5 years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laser trabeculoplasty versus medication, Outcome 6: Failure to stabilise visual field progression at 12 months" data-id="CD003919-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Laser trabeculoplasty versus medication, Outcome 6: Failure to stabilise visual field progression at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laser trabeculoplasty versus medication, Outcome 7: Failure to stabilise visual field progression at 24 months" data-id="CD003919-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Laser trabeculoplasty versus medication, Outcome 7: Failure to stabilise visual field progression at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laser trabeculoplasty versus medication, Outcome 8: Failure to stabilise visual field progression at 48 months" data-id="CD003919-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Laser trabeculoplasty versus medication, Outcome 8: Failure to stabilise visual field progression at 48 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laser trabeculoplasty versus medication, Outcome 9: Failure to stabilise optic neuropathy progression at 24 months" data-id="CD003919-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Laser trabeculoplasty versus medication, Outcome 9: Failure to stabilise optic neuropathy progression at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laser trabeculoplasty versus medication, Outcome 10: Adverse effects: PAS formation" data-id="CD003919-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Laser trabeculoplasty versus medication, Outcome 10: Adverse effects: PAS formation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Laser trabeculoplasty versus medication, Outcome 11: Adverse effects: early IOP spikes" data-id="CD003919-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Laser trabeculoplasty versus medication, Outcome 11: Adverse effects: early IOP spikes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Laser trabeculoplasty versus trabeculectomy, Outcome 1: Failure to control IOP at 6 months" data-id="CD003919-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Laser trabeculoplasty versus trabeculectomy, Outcome 1: Failure to control IOP at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003919-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/urn:x-wiley:14651858:media:CD003919:CD003919-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Laser trabeculoplasty versus trabeculectomy, Outcome 2: Failure to control IOP at 24 months" data-id="CD003919-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_t/tCD003919-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Laser trabeculoplasty versus trabeculectomy, Outcome 2: Failure to control IOP at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/media/CDSR/CD003919/image_n/nCD003919-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003919-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Laser trabeculoplasty versus medication</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Laser trabeculoplasty versus medication</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with open‐angle glaucoma<br/><b>Setting:</b> eye hospital<br/><b>Intervention:</b> laser trabeculoplasty<br/><b>Comparison:</b> medication </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of eyes (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with medication</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with laser trabeculoplasty</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to control IOP</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Considerable clinical and methodological diversity leading to statistical heterogeneity (I<sup>2</sup> = 89%). Risk ratios ranged from 0.43 in favour of laser trabeculoplasty to 1.87 in favour of medication. Studies of argon laser compared with medication were more likely to show a beneficial effect compared with studies of selective laser (test for interaction P = 0.0001) but the argon laser studies were older and the medication comparator group in those studies may have been less effective. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to stabilise visual field progression</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/>(44 to 122) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/>(0.42 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both studies of argon laser. </p> <p>One further study found RR 0.65 (0.52 to 0.81) in favour of selective laser at 48 months.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to stabilise optic neuropathy progression</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/>(44 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73 (0.44 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1,2,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both studies of argon laser. One further study found RR of 0.68 (0.11 to 4.08) in favour of selective laser at 36 months ( 5 events only).  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measures</p> <p>follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One study reported little difference in scores on 12 domains of the GOAT (Glaucoma Outcomes Assessment Tool) at 24 months with the exception of 'social well‐being' whereby participants treated with selective laser reported a greater improvement (MD 0.28, 95% CI  0.03 to 0.53) but it was unclear if this difference was important to patients.  </p> <p>One study reported quality of life as measured using EuroQol EQ‐5D 5 Levels was similar comparing selective laser and medication groups at 36 months (MD 0.01, 95% CI –0.01 to 0.03; P = 0·23).  </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>819 people (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects:<br/>PAS formation </p> <p>follow‐up: any time point</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1000<br/>(149 to 580) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 11.74<br/>(5.94 to 23.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both these studies were argon laser. No PAS events observed in three studies of selective laser. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects: IOP spikes</p> <p>follow‐up: any time point</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>21/429 (5%) of participants in the laser group had early IOP spikes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>429</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All three studies were selective laser.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Costs</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One UK‐based study considered ophthalmology costs and used a willingness‐to‐pay cut‐point of  £20,000 per quality‐adjusted life‐year gained. There was a strong probability (97%) that selective laser (as first‐line treatment) was more cost‐effective than topical medication (as first‐line treatment).  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1235 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is the median risk across the included studies.<br/><b>CI:</b> Confidence interval;<b>IOP:</b> intraocular pressure; <b>PAS</b> : peripheral anterior synechiae; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different </p> <p><b>Low‐certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different </p> <p><b>Very low‐certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): the trials were not masked. </p> <p><sup>2</sup>Downgraded for inconsistency (‐1): unexplained heterogeneity with study results ranging from 0.43 to 1.87 (for outcome, failure to control IOP) and between 0.5 and 1.0 (for outcome, failure to stablise optic neuropathy progression).  </p> <p><sup>3</sup>We did not downgrade for imprecision because an additional study at 48 months found a statistically significant effect of a similar order of magnitude. </p> <p><sup>4</sup>Downgraded for inconsistency (‐1): PAS events only seen in studies of argon laser </p> <p><sup>5</sup>Downgraded for imprecision (‐1): confidence intervals included risk ratios compatible with benefit or harm.  </p> <p><sup>6</sup>Downgraded for indirectness (‐1): results may not generalise globally.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Laser trabeculoplasty versus medication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003919-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Laser trabeculoplasty versus trabeculectomy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Laser trabeculoplasty versus trabeculectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with open‐angle glaucoma<br/><b>Setting:</b> eye hospital<br/><b>Intervention:</b> laser trabeculoplasty<br/><b>Comparison:</b> trabeculectomy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of eyes (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with trabeculectomy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with laser trabeculoplasty</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to control IOP</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1000<br/>(115 to 249) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.12</p> <p>(1.44 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>901<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1,2</sup><br/>LOW </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> = 68% </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to stabilise visual field progression</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Limited data from follow‐up in one study suggested evidence of greater deterioration in the (argon) laser group compared with trabeculectomy at 5 years follow‐up.  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1,3</sup><br/>LOW </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Failure to stabilise optic neuropathy progression</p> <p>(as defined by study investigators)<br/>follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not reported in the included trials.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects<br/>PAS formation </p> <p>follow‐up: any time point</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="2" valign="top"> <p>PAS formation and IOP spikes not reported, but in one study trabeculectomy was associated with an increased risk of cataract (RR 1.78, 95% CI 1.46 to 2.16). </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>789 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<sup>1,4</sup> </p> <p>VERY LOW<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects: IOP spikes</p> <p>follow‐up: any time point </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is the median risk across the included studies. </p> <p>** No events were observed with medication. We have assumed a low risk for illustrative purposes.<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b><br/>  </p> <p><b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different </p> <p><b>Low‐certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different </p> <p><b>Very low‐certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): none of the studies were masked and one study was at high risk of attrition bias. </p> <p><sup>2</sup>Downgraded for inconsistency (‐1): I<sup>2</sup> = 68% </p> <p><sup>3</sup>Downgraded for imprecision (‐1): wide confidence intervention crossed the line of no effect. </p> <p><sup>4</sup>Downgraded for imprecision (‐2): sparse data.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Laser trabeculoplasty versus trabeculectomy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003919-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>People</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Eyes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Average age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Age range</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% female</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>% black</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Clustered (one or two eyes) or paired (within‐person) design</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>591</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>789</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 to 80</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58 to 73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweden</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Norway</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 to 89</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Italy</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 to 67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0011" title="BelkinM , GeffenN , OfirS , MessasAK , BarkanaY , BelkinA , et al. Direct Trans-scleral Selective laser Trabeculoplasty (SLT) without a gonioscopy lens. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 819. GeffenN , OfirS , BelkinA , SegevF , BarkanaY , MessasAK , et al. Transscleral selective laser trabeculoplasty without gonioscopy lens. Journal of Glaucoma2017;26(3):201-7. ">Geffen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Israel</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 to 80</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia, New Zealand, Singapore, UK (15 sites)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77% Caucasian 20% Asian</p> <p>3% other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0014" title="GoldenfeldM , MelamedS , SimonG , SimonGJB . Titanium: sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open angle glaucoma. Ophthalmic Surgery, Laser and Imaging2009;40(3):264-9. ">Goldenfeld 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Israel</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 to 91</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0015" title="GraysonD , RitchR , CamrasC , LustgartenJ , PodosS . Influence of treatment protocol on the long-term efficacy of argon laser trabeculoplasty. Journal of Glaucoma1993;2(7):7-12. LustgartenJ , PodosSM , RitchR , FischerR , StetzD , ZborowskiL , et al. Laser trabeculoplasty. A prospective study of treatment variables. Archives of Ophthalmology1984;102(4):517-9. ">Grayson 1993</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 to 92</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0016" title="GraysonD , ChiT , LiebmannJ , RitchR . Initial argon laser trabeculoplasty to the inferior vs superior half of trabecular meshwork. Archives of Ophthalmology1994;112(4):446-7. ">Grayson 1994</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0017" title="HugkulstoneCE . Argon laser trabeculoplasty with standard and long duration. Acta Ophthalmologica1990;68(5):579-81. HugkulstoneCE . Two-year follow-up of intra-ocular pressure control with long duration argon laser trabeculoplasty. Ophthalmologica1993;71(3):327-31. ">Hugkulstone 1990</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0020" title="KentSS , HutnikCM , BirtCM , DamjiKF , HarasymowyczP , SiF , et al. A randomized clinical trial of selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with pseudoexfoliation. Journal of Glaucoma2015;24(5):344-7. ">Kent 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tanzania</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>201</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>382</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>718</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1235</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 to 60 </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Switzerland</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 to 73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0027" title="MoriartyBJ , CharJN , AchesonRW , DunnDT . Argon laser trabeculoplasty in primary open-angle glaucoma - results in black Jamaican population. International Ophthalmology1988;12(4):217-21. ">Moriarty 1988</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jamaica</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 to 77</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 to 90</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0030" title="RosenfeldE , ShemeshG , KurtzS . The efficacy of selective laser trabeculoplasty versus argon laser trabeculoplasty in pseudophakic glaucoma patients. Clinical Ophthalmology2012;6:1935-40. [DOI: 10.2147/OPTH.S34193]">Rosenfeld 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Israel</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0031" title="RouhiainenHJ , TerasvirtaME , TuovinenEJ . Peripheral anterior synechiae formation after trabeculoplasty. Archives of Ophthalmology1988;106(2):189-91. RouhiainenHJ , TerasvirtaME , TuovinenEJ . The effect of some treatment variables on the results of trabeculoplasty. Archives of Ophthalmology1988;106(5):611-3. ">Rouhiainen 1988</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finland</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51 to 87</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 to 90</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0033" title="SmithJ . Argon laser trabeculoplasty: comparison of bichromatic and monochromatic wavelengths. Ophthalmology1984;91(4):355-60. ">Smith 1984</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0034" title="TangM , FuY , FuMS , FanY , ZouHD , SunXD , et al. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surgery, Lasers and Imaging2011;42(1):59-63. [DOI: http://dx.doi.org/10.3928/15428877-20101124-07]TangM , FuY , MaY , FuM , FanY , SunX , et al. The efficacy of low-energy selective laser trabeculoplasty. Chinese Journal of Ophthalmology2011;47(10):887-92. ">Tang 2011</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 to 79</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0035" title="TufanAK , OnurIU , YiğitFU , AğaçhanA , NacaSA . Selective laser trabeculoplasty vs. fixed combinations with timolol in practice: a replacement study in primary open angle glaucoma. Turkish Journal of Ophthalmology2017;47:198-204. ">Tufan  2017</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within‐person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38  to 86</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China (Hong Kong)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malaysia</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54 to 81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70% Chinese, 30% Malay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0039" title="ZhangH , YangY , XuJ , YuM . A prospective randomized study of selective laser trabeculoplasty (SLT) as a replacement for medial therapy in primary open angle glaucoma. Zhonghua Yan Ke Za Zhi2015;51(2):109-14. ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selctive laser trabeculoplasty in primary patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. [DOI: 10.1155/2016/2153723]">Zhang 2015</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 to 72</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clustered</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0040" title="ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selective laser trabeculoplasty in patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. ">Zhang 2016</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>China</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One eye per person</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median: 67</p> <p>Min: 45</p> <p>Max: 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall range: 18 to 92 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median: 52</p> <p>Min: 13</p> <p>Max: 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003919-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Studies comparing laser trabeculoplasty with medication</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of uncontrolled IOP</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0004" title="BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. II: Long-term effects on intraocular pressure and facility of outflow. Study design and additional therapy. Acta Ophthalmologica1994;72(2):145-54. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine. III. Long-term effects on visual fields. Acta Ophthalmologica Scandinavica1995;73(3):207-15. BergeaB , BodinL , SvedberghB . Primary argon laser trabeculoplasty vs pilocarpine IV. Long-term effects on optic nerve head. Acta Ophthalmologica Scandinavica1995;73(3):216-21. BergeaB , SvedberghB . Primary argon laser trabeculoplasty vs. pilocarpine. Short-term effects. Acta Ophthalmologica1992;70(4):454-60. SvedberghB , BodinL , BergeaB . Primary argon laser trabeculoplasty versus pilocarpine. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3762. ">Bergea 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pilocarpine 4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP &gt; 26 mmHg or clinically evident visual field decay</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0010" title="GandolfiS , ChettaA , CiminoK , MoraP , SangermaniC , TardiniG . Bronchial reactivity in healthy individuals undergoing long-term treatment with beta-blockers. Archives of Ophthalmology2005;123(1):35-8. ">Gandolfi 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Timolol 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or greater</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0012" title="AngGS , FenwickEK , ConstantinouM , GanATL , ManREK , CassonRJ , et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the Glaucoma Initial Treatment study randomised clinical trial. British Journal of Ophthalmology2020;104(6):813-21. [DOI: 10.1136/bjophthalmol-2018-313396]LamoureuxEL , McintoshR , ConstantinouM , FenwickEK , XieJ , CassonR , et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials2015;11(16):406. [DOI: 10.1186/s13063-015-0924-6]">Glaucoma Initial Treatment Study 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG or PXF, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostaglandin analogue eye drop (latanoprost<br/>0.005%, travoprost 0.004%, bimatoprost 0.03% or tafluprost 0.0015%). If the IOP was not sufficiently well‐controlled, a stepped regimen of topical medications was followed which included the addition of beta‐adrenergic antagonists, alpha agonists and carbonic anhydrase inhibitors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less than or equal to 10% IOP reduction since baseline </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0013" title="Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. Ophthalmic Surgery1991;22(6):324-9. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 3. Design and methods. Controlled Clinical Trials1991;12(4):504-24. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Ophthalmic Surgery1993;24(4):232-40. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. American Journal of Ophthalmology1995;120(1):10-22. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology1990;97(11):1403-13. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. American Journal of Ophthalmology1995;120(6):718-31. KiriA , SpaethG , BeckmanH , SternbergA , GLT Research Group. Optic disc characteristics of blacks and whites in the glaucoma laser trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 1187. SternbergA , KiriA , BeckmanH , SpaethG , GLT Research Group. Quantitative optic disk characteristics in hypertensive POAG, and diabetic POAG patients in the glaucoma laser trial. Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 394. WilenskyJT , BeckmanH , MeinerCL , RitchR , SternbergAL , Glaucoma Laser Trabeculoplasty Study Group. Contribution of each treatment session to IOP reduction resulting from split therapy ALT in the Glaucoma Laser Trial (GLT). Investigative Ophthalmology and Visual Science1994;35:ARVO E-abstract 3761. ">GLT 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Timolol 0.5%</p> <p>Step 1: 0.5% timolol, twice a day<br/>Step 2: 0.1% dipivefrin, twice a day </p> <p>Step 3: Low‐dose pilocarpine, four times a day<br/>Step 4: High‐dose pilocarpine, four times a day<br/>Step 5: 0.5% timolol, twice a day with high dose pilocarpine, four times a day<br/>Step 6: 0.1% dipivefrin, twice a day with high dose pilocarpine, four times a day<br/>Step 7: Release from stepped regimen; treatment at discretion of GLT ophthalmologist </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or more</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0019" title="KatzLJ , SteinmannWC , KabirA , MolineauxJ , WizovSS , MarcellinoG , et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Journal of Glaucoma2012;21(7):460-8. [DOI: 10.1097/IJG.0b013e318218287f]">Katz 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG or OHT, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>timolol or<br/>betaxolol<br/>Step 3: Brimonidine<br/>Step 4: Dorzolamide, brinzolamide or a fixed‐combination<br/>dorzolamide‐timolol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Target IOP was determined using the Collaborative Initial Glaucoma Treatment Study<br/>formula. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0021" title="PhilippinH , MatayanE , KnollKM , MachaE , MbishiS , MakupaA , et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. Lancet Global  Health2021;9(11):e1589-e99. [DOI: 10.1016/S2214-109X(21)00348-X]">KiGIG 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG or OHT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Timolol 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP below or equal to target pressure according to glaucoma severity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0022" title="LaiJS , ChuaJK , ThamCC , LamDS . Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clinical Experimental Ophthalmology2004;32(4):368-72. ">Lai 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG or OHT, newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>β‐blocker, pilocarpine, dorzolamide and latanoprost either as monotherapy or in combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 21 mmHg on maximal therapy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0023" title="GargA ,  VickerstaffV ,  NathwaniN ,  Garway-HeathD ,  KonstantakopoulouE ,  AmblerG ,  et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology2019;126(9):1238-48. GargA , VickerstaffV , NathwaniN , Garway-HeathD , KonstantakopoulouE , AmblerG , et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmology2020;127(4):467-76. GargA , VickerstaffV , NathwaniN , KonstantakopoulouE , DowseE , GazzardG . Primary selective laser trabeculoplasty for primary open angle glaucoma &amp; ocular hypertension: early clinical outcomes from a prospective, multi-centre randomised controlled UK trial. Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 6091. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  BartonK ,  WormaldR ,  MorrisS ,  et al. Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. British Journal of Ophthalmology2018;102(5):593-8. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessesment2019;23(31):1-102. GazzardG ,  KonstantakopoulouE ,  Garway-HeathD ,  GargA ,  VickerstaffV ,  HunterR ,  et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet2019;393(10180):1505-16. KonstantakopoulouE ,  GazzardG ,  VickerstaffV ,  JiangY ,  NathwaniN ,  HunterR ,  et al. The Laser in Glaucoma and ocular Hypertension (LiGHT) Trial. A multicentre randomised controlled trial: baseline patient characteristics. British Journal of Ophthalmology2018;102(5):599-603. VickerstaffV ,  AmblerG ,  BunceC ,  XingW ,  GazzardG ,  LiGHT Trial Study Group. Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials2015;16:517. ">LIGHT 2019</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG or OHT, newly diagnosed<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT followed by topical medication as required<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mainstream topical IOP‐lowering medication<br/>Medication classes for first‐, second‐ or third‐line treatment as per NICE1 European Glaucoma Society guidance: </p> <p>first‐line: prostaglandin analogue<br/>second‐line: beta‐blocker (alone or in combination with prostaglandin analogue combination)<br/>third‐ or fourth‐line: topical carbonic anhydrase inhibitor or alpha‐adrenoceptor agonist.<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not defined<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG but unclear if newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pilocarpine and/or a sympathomimetic and/or timolol as initial therapy, increasing to maximum‐tolerated medical therapy which could require up to three topical medications and a carbonic anhydrase inhibitor </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or greater</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0027" title="MoriartyBJ , CharJN , AchesonRW , DunnDT . Argon laser trabeculoplasty in primary open-angle glaucoma - results in black Jamaican population. International Ophthalmology1988;12(4):217-21. ">Moriarty 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, on maximum medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT and medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pilocarpine 4% and acetazolamide 250mg four times a day. Four participants used timolol 0.5%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or greater</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0028" title="NagarM ,   HowesFW . Selective laser trabeculoplasty: a randomized controlled trial. In: American Academy of Ophthalmology; 2003. 2003:135-6. NagarM , LuhishiE , ShahN . Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology2009;93(4):497-501. NagarM , OgunyomadeA , O'BrartDP , HowesF , MarshallJ . A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. British Journal of Ophthalmology2005;89(11):1413-7. ">Nagar 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG or OHT newly diagnosed or controlled on medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Latanaprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not defined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0032" title="SherwoodMB , LattimerJ , HitchingsRA . Laser trabeculoplasty as supplementary treatment for primary open angle glaucoma. British Journal of Ophthalmology1987;71(3):188-91. ">Sherwood 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, on maximum medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum medical therapy (not specified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drop of IOP of less than 20% or IOP reading 22mmHg or greater</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0035" title="TufanAK , OnurIU , YiğitFU , AğaçhanA , NacaSA . Selective laser trabeculoplasty vs. fixed combinations with timolol in practice: a replacement study in primary open angle glaucoma. Turkish Journal of Ophthalmology2017;47:198-204. ">Tufan  2017</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed combinations: timolol maleate 0.5%, bimatoprost 0.03%, travoprost 0.004%, and latanoprost 0.005%, or timolol maleate 0.5%, dorzolamide hydrochloride 2%, brinzolamide 1%, and brimonidine tartrate 0.2% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Not defined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0038" title="YongMH , Che HamzahJ . Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness. Medical Journal of Malaysia2020;75(4):342-8. ">Yong 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Current medications. Quote "Patients in the MED group were advised to step‐up their topical anti‐glaucoma medications by adding another topical anti‐glaucoma medication group until achieving target IOP. The step‐up regimen was following the sequence of adding first prostaglandin group, followed by β‐blocker, α2‐agonist, and carbonic anhydrase inhibitor." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not defined</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ALT: argon laser trabeculoplasty<br/>GLT: Glaucoma Laser Trial<br/>IOP: intraocular pressure<br/>MED: medication<br/>OAG: primary or secondary open‐angle glaucoma<br/>OHT: ocular hypertension<br/>POAG: primary open‐angle glaucoma<br/>PXF: pseudoexfoliation glaucoma<br/>SLT: selective laser trabeculoplasty </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Studies comparing laser trabeculoplasty with medication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003919-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Studies comparing laser trabeculoplasty with trabeculectomy</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trabeculectomy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of uncontrolled IOP</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0002" title="AGIS (Advanced Glaucoma Intervention Study) Investigators. The advanced glaucoma intervention study, 8: Risk of cataract formation after trabeculectomy. Archives of Ophthalmology2001;119(12):1771-9. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology2001;132(3):311-20. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology1998;105(7):1137-45. Anonymous. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology1998;105(7):1146-64. CaprioliJ , ColemanA . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention study. Ophthalmology2008;115(7):1123-9. EdererF , GaasterlandDA , DallyLG , KimJ , VanVeldhuisenPC , BlackwellB , et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results. Ophthalmology2004;111(4):651-64. GaasterlandDE , BlackwellB , DallyLG , CaprioliJ , KatzLJ , EdererF , et al. The Advanced Glaucoma Intervention Study (AGIS): 10. Variability among academic glaucoma subspecialists in assessing optic disc notching. Transactions of the American Ophthalmological Society2001;99:177-85. SchwartzAL , VanVeldhuisenPC , GaasterlandDE , EdererF , SullivanEK , CyrlinMN , et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. American Journal of Ophthalmology1999;127(1):8-19. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 2. Visual field: method of scoring and reliability. Ophthalmology1994;101(8):1445-55. The AGIS Investigators. The Advanced Glaucoma Intervention Study, 6: effect of cataract on visual field and visual acuity. Archives of Ophthalmology2000;118(12):1639-52. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods, and baseline characteristics of study patients. Controlled Clinical Trials1994;15(4):299-325. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology2002;134(4):481-93. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. American Journal of Ophthalmology2002;134(4):499-512. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology2000;130(4):429-40. ">AGIS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trabeculectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant met criteria for a further glaucoma intervention.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0026" title="HitchingsR , MigdalC , FitzkeF . Intraocular pressure: does it protect the visual fields? In: Glaucoma Update IV. Berlin; Heidelberg: Springer-Verlag, 1991. HitchingsR , MigdalC , GregoryW , PoinooswamyD , FitzkeF . The use of Humphrey Perimeter to identify visual loss. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. HitchingsR , MigdalC , WormaldR , PoinooswamyD , FitzkeF . The primary treatment trial: changes in the visual field analysis by computerised-assisted perimetry. Eye1994;8(Pt 1):117-20. McHamM , MigdalC , NetlandP . Early trabeculectomy in the management of primary open angle glaucoma. International Ophthalmology Clinics1994;34(3):163-72. MigdalC , ClarkP , HitchingsC . Glaucomatous field changes related to the method and the degree of intraocular pressure control. Documenta Ophthalmologica1987;49:371-6. MigdalC , GregoryW , HitchingsR . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology1994;101(10):1651-6. MigdalC , HitchingsR , GregoryM . Effect of mean IOP levels on visual field preservation in treated glaucoma patients. In: Annual Congress of Royal College of Ophthalmologists; May 1993. 1993. MigdalC , HitchingsR . Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Transactions of the Ophthalmological Societies of the United Kingdom1986;105(Pt 6):653-6. MigdalC , HitchingsR . Primary therapy for chronic simple glaucoma: the role of argon laser trabeculoplasty. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):62-6. MigdalC , HitchingsR . The role of early surgery for open angle glaucoma. Ophthalmology Clinics of North America1991;4(4):853-9. MigdalC . What is the appropriate treatment for patients with primary open angle glaucoma: medicine, laser or primary surgery. Ophthalmic Surgery1995;26(2):108-9. ">Moorfields PTT 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG but unclear if newly diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trabeculectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or more</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0036" title="WatsonPG , AllenED , GrahamCM , PorterGP , PickeringMS . Argon laser trabeculoplasty or trabeculectomy: a prospective randomised block study. Transactions of the Ophthalmological Societies of the United Kingdom1984;104(Pt 1):55-61. ">Watson 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard technique with a fornix based flap</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuous IOP only</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>IOP: intraocular pressure<br/>OAG: primary or secondary open‐angle glaucoma<br/>POAG: primary open‐angle glaucoma </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Studies comparing laser trabeculoplasty with trabeculectomy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003919-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Studies comparing different lasers</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of uncontrolled IOP</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>uncontrolled OAG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>On maximally tolerated medical therapy with the need for additional IOP lowering. Proportion success defined as  &gt;= 3 mmHg IOP decrease or &gt;= 20.0% IOP decrease from baseline<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excimer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP less than 20% compared with baseline values or needing to increase the number of glaucoma medications from pretreatment level </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, uncontrolled on maximum medical dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 mmHg or more</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, on maximum tolerated medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP less than 20% compared with baseline values or needing to increase the number of glaucoma medications from pretreatment level </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG, on maximum tolerated medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for trabeculectomy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG, uncontrolled on maximum medical therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less than 20% IOP reduction</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0014" title="GoldenfeldM , MelamedS , SimonG , SimonGJB . Titanium: sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open angle glaucoma. Ophthalmic Surgery, Laser and Imaging2009;40(3):264-9. ">Goldenfeld 2009</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG, uncontrolled IOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Titanium‐sapphire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Success: reduction in IOP to 18 mm Hg or less, or by 30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary OAG or OHT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Titanium‐sapphire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Success: IOP &lt; 21 mm Hg with &gt; 20% decrease in IOP as compared with baseline without the need for further glaucoma procedures </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0020" title="KentSS , HutnikCM , BirtCM , DamjiKF , HarasymowyczP , SiF , et al. A randomized clinical trial of selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with pseudoexfoliation. Journal of Glaucoma2015;24(5):344-7. ">Kent 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG or OHT due to pseudoexfoliation syndrome, medically uncontrolled IOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Success/failure not defined<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG</p> <p>uncontrolled on topical medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"A complete success was defined as sustaining an IOP decrease from a baseline of more than 20% or of 3 mm Hg or greater, without undergoing further laser or surgery." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OAG, uncontrolled on topical medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pattern scanning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 20% decrease in IOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0030" title="RosenfeldE , ShemeshG , KurtzS . The efficacy of selective laser trabeculoplasty versus argon laser trabeculoplasty in pseudophakic glaucoma patients. Clinical Ophthalmology2012;6:1935-40. [DOI: 10.2147/OPTH.S34193]">Rosenfeld 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, pseudoexfoliation glaucoma, pigmentary glaucoma, or ocular hypertension (OHT), uncontrolled on topical medication </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>decrease of &lt; 15% in IOP from baseline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG and OHT recently diagnosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pattern scanning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 20% decrease in IOP</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ALT: argon laser trabeculoplasty<br/>IOP: intraocular pressure<br/>MLT: micropulse laser trabeculoplasty<br/>OAG: primary or secondary open‐angle glaucoma<br/>OHT: ocular hypertension<br/>POAG: primary open‐angle glaucoma<br/>SLT: selective laser trabeculoplasty<br/>  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Studies comparing different lasers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003919-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Studies comparing modifications of laser trabeculoplasty technique or regimens</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Type of laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Technique</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of uncontrolled IOP</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0009" title="ElsasT , JohnsenH , BrevikTA . The immediate pressure response to primary laser trabeculoplasty - a comparison of one- and two-stage treatment. Acta Ophthalmologica1989;67(6):664-8. ">Elsas 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180º x 360º</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Newly diagnosed OAG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP &lt; 21 mmHg, VF deterioration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0011" title="BelkinM , GeffenN , OfirS , MessasAK , BarkanaY , BelkinA , et al. Direct Trans-scleral Selective laser Trabeculoplasty (SLT) without a gonioscopy lens. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 819. GeffenN , OfirS , BelkinA , SegevF , BarkanaY , MessasAK , et al. Transscleral selective laser trabeculoplasty without gonioscopy lens. Journal of Glaucoma2017;26(3):201-7. ">Geffen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transcleral x conventional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG and exfoliation uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP decrease &lt; 15%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0015" title="GraysonD , RitchR , CamrasC , LustgartenJ , PodosS . Influence of treatment protocol on the long-term efficacy of argon laser trabeculoplasty. Journal of Glaucoma1993;2(7):7-12. LustgartenJ , PodosSM , RitchR , FischerR , StetzD , ZborowskiL , et al. Laser trabeculoplasty. A prospective study of treatment variables. Archives of Ophthalmology1984;102(4):517-9. ">Grayson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180º x 360º</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG and exfoliation uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need of further intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0016" title="GraysonD , ChiT , LiebmannJ , RitchR . Initial argon laser trabeculoplasty to the inferior vs superior half of trabecular meshwork. Archives of Ophthalmology1994;112(4):446-7. ">Grayson 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>superior x inferior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG and exfoliation uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need of further intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0017" title="HugkulstoneCE . Argon laser trabeculoplasty with standard and long duration. Acta Ophthalmologica1990;68(5):579-81. HugkulstoneCE . Two-year follow-up of intra-ocular pressure control with long duration argon laser trabeculoplasty. Ophthalmologica1993;71(3):327-31. ">Hugkulstone 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1 sec x 0.2 sec</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG, pigmentary glaucoma and exfoliation uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuous IOP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0029" title="ÖzenB , ÖztürkH , YüceB . Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea. International Ophthalmology2020;40(5):1103-10. [DOI: 10.1007/s10792-019-01275-6]">Ozen 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180º x 360º</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bilateral POAG uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP decrease &lt; 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0031" title="RouhiainenHJ , TerasvirtaME , TuovinenEJ . Peripheral anterior synechiae formation after trabeculoplasty. Archives of Ophthalmology1988;106(2):189-91. RouhiainenHJ , TerasvirtaME , TuovinenEJ . The effect of some treatment variables on the results of trabeculoplasty. Archives of Ophthalmology1988;106(5):611-3. ">Rouhiainen 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different power levels (500 mW x 800 mW)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG and exfoliation uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP ≥ 21 mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0033" title="SmithJ . Argon laser trabeculoplasty: comparison of bichromatic and monochromatic wavelengths. Ophthalmology1984;91(4):355-60. ">Smith 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Continuous‐wave laser (green) x blue‐green continuous‐wave laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need of further intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0034" title="TangM , FuY , FuMS , FanY , ZouHD , SunXD , et al. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surgery, Lasers and Imaging2011;42(1):59-63. [DOI: http://dx.doi.org/10.3928/15428877-20101124-07]TangM , FuY , MaY , FuM , FanY , SunX , et al. The efficacy of low-energy selective laser trabeculoplasty. Chinese Journal of Ophthalmology2011;47(10):887-92. ">Tang 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low energy x normal energy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0039" title="ZhangH , YangY , XuJ , YuM . A prospective randomized study of selective laser trabeculoplasty (SLT) as a replacement for medial therapy in primary open angle glaucoma. Zhonghua Yan Ke Za Zhi2015;51(2):109-14. ZhangHY , QinYJ , YangYF , XuJG , YuMB . Intraocular pressure-lowering potential of subthreshold selctive laser trabeculoplasty in primary patients with primary open-angle glaucoma. Journal of Ophthalmology2016;2016:Article ID 2153723. [DOI: 10.1155/2016/2153723]">Zhang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SLT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low energy x normal energy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>POAG uncontrolled on medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP changes, changes in types of medication use, intervention success, daytime IOP fluctuation and complications </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ALT: argon laser trabeculoplasty<br/>IOP: intraocular pressure<br/>mW: milliwatts<br/>OAG: primary or secondary open‐angle glaucoma<br/>OHT: ocular hypertension<br/>POAG: primary open‐angle glaucoma<br/>SLT: selective laser trabeculoplasty<br/>VF: visual field </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Studies comparing modifications of laser trabeculoplasty technique or regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003919-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Studies comparing different lasers: failure to control IOP</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Diode</b> </p> <p><b>(3 studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Selective</b> </p> <p><b>(4 studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Titanium‐sapphire</b> </p> <p><b>(1 study)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Excimer</b> </p> <p><b>(1 study)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pattern scanning</b> </p> <p><b>(2 studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Titanium‐sapphire</b> </p> <p><b>(1 study)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Micropulse (1 study)</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Comparator: argon</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>                                Comparator: selective</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85</p> <p>(0.16 to 4.64)</p> <p>(1 study, n=50)</p> <p><a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 </p> <p>(0.44 to 2.29)</p> <p>(1 study, n=63)</p> <p><a href="./references#CD003919-bbs2-0020" title="KentSS , HutnikCM , BirtCM , DamjiKF , HarasymowyczP , SiF , et al. A randomized clinical trial of selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with pseudoexfoliation. Journal of Glaucoma2015;24(5):344-7. ">Kent 2013</a> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63% of the eyes were considered failures in PLT group and 74% in SLT group (p=0.09)</p> <p>(n=58)</p> <p> <a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Proportion success defined as  &gt;= 3 mmHg IOP decrease or &gt;= 20.0% IOP decrease from baseline: MLT 29.6% vs SLT 36.0% (P = 0.77). </p> <p>(n=38)</p> <p><a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a><br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73</p> <p>(0.26 to 2.11)</p> <p>(2 studies, n=70)</p> <p><a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a>; <a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25</p> <p>(0.84 to 1.84)</p> <p>(1 study, n = 153) </p> <p><a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a> </p> <p>0.39 </p> <p>(0.15 to 0.97) </p> <p>(1 study, n=33)</p> <p> <a href="./references#CD003919-bbs2-0030" title="RosenfeldE , ShemeshG , KurtzS . The efficacy of selective laser trabeculoplasty versus argon laser trabeculoplasty in pseudophakic glaucoma patients. Clinical Ophthalmology2012;6:1935-40. [DOI: 10.2147/OPTH.S34193]">Rosenfeld 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was a reduction of 8.3 mmHg (SD 2.7) in TLT group (n = 18) and 6.5 mmHg (SD 4.3) in the ALT group (n = 17).  </p> <p><a href="./references#CD003919-bbs2-0014" title="GoldenfeldM , MelamedS , SimonG , SimonGJB . Titanium: sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open angle glaucoma. Ophthalmic Surgery, Laser and Imaging2009;40(3):264-9. ">Goldenfeld 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>Failure rate of 74.6% in SLT group and 84.6% in PLT group (p=0.155) (n=132)</p> <p><a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Failure rates of 56% in TLT group and 39% in SLT group (p=0.11) (n=37). </p> <p><a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> <p>(0.35 to 1.94)</p> <p>(2 studies, n=90)</p> <p><a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a>; <a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01</p> <p>(0.76 to 1.33)</p> <p>(2 studies, n=97)</p> <p><a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; <a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The cumulative probability of complete success was 53% for excimer laser vs 40% for SLT  (p=0.35) (n=30) </p> <p><a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In <a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a>, at two years, rates increased to 78% in TLT and 54% in SLT (p=0.11) </p> <p>(n=37)</p> <p><a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a>  </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion success at 12 months: <br/>MLT 37.0%, SLT 36.0% (P = 1.0)  </p> <p>(n=38)</p> <p><a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ALT: argon laser trabeculoplasty<br/>IOP: intraocular pressure<br/>MLT: micropulse laser trabeculoplasty<br/>NR: not reported<br/>PLT:  pattern‐scanning laser trabeculoplasty <br/>SD:  standard deviation<br/>SLT: selective laser trabeculoplasty<br/>TLT:  titanium‐sapphire laser trabeculoplasty </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Studies comparing different lasers: failure to control IOP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003919-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Studies comparing different lasers: adverse effects</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Argon laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Selective laser</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other lasers</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0001" title="AbramowitzB , ChadhaN , KouchoukA , AlhabshanR , BelyeaDA , LambaT . Selective laser trabeculoplasty vs micropulse laser trabeculoplasty in open-angle glaucoma. Clinical Ophthalmology2018;12:1599-1604. ">Abramowitz 2018</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Micropulse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> "The MLT patients on average experienced less pain both during and after the treatment (P = 0.005)." "An IOP spike was defined as an elevation of.5 mmHg from the pretreatment mean. Incidence of post‐procedure spikes were 5.3% and 12.9% in the MLT and SLT groups, respectively, but this difference was not statistically significant (P = 0.4)." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0003" title="BabighianS , CarettiL , TavolatoM , CianR , GalanA . Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye2010;24(4):632-8. [DOI: 10.1038/eye.2009.172]">Babighian 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excimer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no difference in IOP spikes between the two groups of treatment (2/15 eyes in ELT versus 3/15 eyes in SLT group (RR 0.67, 95% CI 0.13 to 3.44). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0005" title="BlythCPJ , MoriartyAP , McHughJDA . Diode laser trabeculoplasty versus argon laser trabeculoplasty in the control of primary open angle glaucoma. Lasers in Medical Science1999;14(2):105-8. MoriartyAP , McHughJD , FfytcheTJ , MarshallJM , SpaltonDJ , MoriartyBJ . Diode laser trabeculoplasty (DLT) versus argon laser trabeculoplasty (ALT) in primary open angle glaucoma. In: American Academy of Ophthalmology; 1994. Vol. 107. 1994. ">Blyth 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP spikes: two eyes in each group had an increase of more than 5 mmHg after two hours postoperatively. </p> <p>PAS formation: Four eyes of the argon group developed PAS (RR 0.54; 95% CI 0.17 to 1.76). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0006" title="BrancatoR , CarassaR , TrabucchiG . Diode laser compared with argon laser for trabeculoplasty. American Journal of Ophthalmology1991;112(1):50-5. ">Brancato 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP spikes: IOP after trabeculoplasty within two hours postoperatively and did not observe any IOP elevation greater than 5 mmHg in either group. </p> <p>PAS formation: no goniosynechiae formation was observed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP spikes: an increase in IOP from baseline of 2 to 6 mmHg in the first hour postoperatively in two eyes of the diode group and five eyes in the argon laser group. After 24 hours from the laser procedures in both groups, no eye experienced elevated IOP greater than 3 mmHg from baseline. </p> <p>PAS formation: <a href="./references#CD003919-bbs2-0007" title="ChungPY , SchumanJS , NetlandPA , Lloyd-MuhammadRA , JacobsDS . Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. American Journal of Ophthalmology1998;126(2):185-90. ">Chung 1998</a>: some eyes presented at three months with synechiae. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0008" title="BovellAM , DamjiKF , HodgeWG , RockWJ , BuhrmannRR , PanYI . Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty?Canadian Journal of Ophthalmology2011;46(5):408-13. [DOI: 10.1016/j.jcjo.2011.01.016]DamjiKF , BovellAM , HodgeWG , RockW , ShahK , BuhrmanR , et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial trabeculoplasty: results from a 1-year randomised clinical trial. British Journal of Ophthalmology2006;90(12):1490–4. DamjiKF , ShahKC , RockWJ , BainsHS , HodgeWG . Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. British Journal of Ophthalmology1999;83(6):718-22. HodgeW , DamjiKF , BovellA , BuhrmannRR . Highly successful SLT is independent of glaucoma type, previous surgery, medical therapy, or glaucoma risk factors. In: American Academy of Ophthalmology; 2002. Vol. 257 (abstract). 2002. HodgeWG , BovellA , RockW , DamjiKF . Selective laser trabeculoplasty vs argon laser trabeculoplasty - a prospective randomized clinical trial. Investigative Ophthalmology and Visual Science2001;42:ARVO E-abstract 2912. HodgeWG , DamjiKF , RockW , BuhrmannR , BovellAM , PanY . Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. British Journal of Ophthalmology2005;89(9):1157-60. ">Damji 2006</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical examination for flare and cells was assessed one hour post‐laser and graded on a scale from 0 (no reaction) to 4 (very marked reaction). There was no difference observed in mean score of flare in anterior chamber between the eyes treated with SLT (1.00, SD 0.6) and eyes treated with laser trabeculoplasty (0.8 SD 0.6). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0014" title="GoldenfeldM , MelamedS , SimonG , SimonGJB . Titanium: sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open angle glaucoma. Ophthalmic Surgery, Laser and Imaging2009;40(3):264-9. ">Goldenfeld 2009</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Titanium‐sapphire<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two patients (1 in each group) had trabeculectomy. Three cases of peripheral anterior synechiae in the ALT group but none in the TLT group.   </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0018" title="KaplowitzK , WangS , BilonickR , OattsJ , GrippoT , LoewenN . Randomized controlled comparison of Titanium-Saphire versus standard Q-Switched Nd:Yag laser trabeculoplasty. Journal of Glaucoma2016;25:e663-e7. ">Kaplovitz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Titanium‐sapphire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP spikes: Three participants in each group experienced spikes &gt; 10 mmHg, but two participants (11%) in TLT maintained an uncontrolled IOP and needed filtering surgeries. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0020" title="KentSS , HutnikCM , BirtCM , DamjiKF , HarasymowyczP , SiF , et al. A randomized clinical trial of selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with pseudoexfoliation. Journal of Glaucoma2015;24(5):344-7. ">Kent 2013</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No IOP spikes in either group (pressure difference of 6 or more after 1 hour)<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0024" title="LiuY ,  BirtCM . Argon versus selective laser trabeculoplasty in younger patients: 2-year results. Journal of Glaucoma2012;21(2):112-5. [DOI: 10.1097/IJG.0b013e318202791c]">Liu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0025" title="MansouriK , ShaarawyT . Comparing pattern scanning laser trabeculoplasty to selective laser trabeculoplasty: a randomized controlled trial. Acta Ophthalmologica2016;95(5):e361-5. ">Mansouri 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pattern scanning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IOP spikes: One patient in SLT group, had a spike of 15 mmHG, and needed a filtering surgery. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0030" title="RosenfeldE , ShemeshG , KurtzS . The efficacy of selective laser trabeculoplasty versus argon laser trabeculoplasty in pseudophakic glaucoma patients. Clinical Ophthalmology2012;6:1935-40. [DOI: 10.2147/OPTH.S34193]">Rosenfeld 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003919-bbs2-0037" title="WongMOM ,  Wai Lai IS, ChanPP , ChanCY , LeungCK . A randomized controlled trial (RCT) comparing the efficacy and safety of pattern laser trabeculoplasty (PLT) and selective laser trabeculoplasty (SLT). Investigative Ophthalmology and Visual Science 2018;59(9):ARVO E-abstract 6098. WongMOM , LaiIS , ChanPP , ChanNC , ChanAY , LaiGW , et al. Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. British Journal Ophthalmology2021;105(4):514–20. [DOI: 10.1136/bjophthalmol-2020-316178]">Wong 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pattern scanning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One patient in PLT group developed a protracted uveitis, that resolved with topical steroids after 6 months. One subject in SLT and one in PLT group had IOP spike in the first day (&gt; 20% IOP). One patient in PLT developed cataracts and one in SLT developed angle closure, and needed an iridotomy. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ALT: argon laser trabeculoplasty<br/>ELT: excimer laser trabeculoplasty<br/>IOP: intraocular pressure<br/>MLT: micropulse laser trabeculoplasty<br/>OAG: primary or secondary open‐angle glaucoma<br/>OHT: ocular hypertension<br/>PLT: pattern scanning laser trabeculoplasty<br/>POAG primary open‐angle glaucoma<br/>SD: standard deviation<br/>SLT: selective laser trabeculoplasty<br/>TLT: titanium‐sapphire laser trabeculoplasty </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Studies comparing different lasers: adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/full#CD003919-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003919-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Laser trabeculoplasty versus medication</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Failure to control IOP at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Argon laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Selective laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Failure to control IOP at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Argon laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.22, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Selective laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.67, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Failure to control IOP at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Argon laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Selective laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Failure to control IOP at 36 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Failure to control IOP at 5 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Failure to stabilise visual field progression at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Failure to stabilise visual field progression at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.42, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Failure to stabilise visual field progression at 48 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Failure to stabilise optic neuropathy progression at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.44, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Adverse effects: PAS formation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.74 [5.94, 23.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Adverse effects: early IOP spikes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.31 [2.75, 74.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Laser trabeculoplasty versus medication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003919-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Laser trabeculoplasty versus trabeculectomy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Failure to control IOP at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [1.72, 6.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Failure to control IOP at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.44, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Laser trabeculoplasty versus trabeculectomy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003919.pub3/references#CD003919-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003919.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003919-note-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003919-note-0022">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003919-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003919-note-0020">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD003919-note-0021">Magyar</a> </li> <li class="section-language"> <a class="" href="id#CD003919-note-0018">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD003919-note-0016">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD003919-note-0017">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003919-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003919-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003919\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003919\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003919\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003919\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003919\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003919.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003919.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003919.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003919.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003919.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727860849"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003919.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727860853"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003919.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb65a6e969368',t:'MTc0MDcyNzg2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 